WO2012075030A1 - Microbial production of natural sweeteners, diterpenoid steviol glycosides - Google Patents

Microbial production of natural sweeteners, diterpenoid steviol glycosides Download PDF

Info

Publication number
WO2012075030A1
WO2012075030A1 PCT/US2011/062428 US2011062428W WO2012075030A1 WO 2012075030 A1 WO2012075030 A1 WO 2012075030A1 US 2011062428 W US2011062428 W US 2011062428W WO 2012075030 A1 WO2012075030 A1 WO 2012075030A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
enzyme
kaurene
catalytically active
active portion
Prior art date
Application number
PCT/US2011/062428
Other languages
French (fr)
Inventor
Gregory Stephanopoulos
Parayil K. Ajikumar
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/249,388 external-priority patent/US8927241B2/en
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to CA2819253A priority Critical patent/CA2819253A1/en
Priority to EP11793960.3A priority patent/EP2645847B1/en
Publication of WO2012075030A1 publication Critical patent/WO2012075030A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H13/00—Algae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/36—Terpene glycosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C12N9/0085—Steroid 17 alpha-monooxygenase (1.14.99.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13076—Taxane 10-beta-hydroxylase (1.14.13.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13078—Ent-kaurene oxidase (1.14.13.78)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99009—Steroid 17-alpha-monooxygenase (1.14.99.9), i.e. cytochrome-P450-steroid-17-alpha-hydroxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/03—Carbon-oxygen lyases (4.2) acting on phosphates (4.2.3)
    • C12Y402/03019—Ent-kaurene synthase (4.2.3.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y505/00—Intramolecular lyases (5.5)
    • C12Y505/01—Intramolecular lyases (5.5.1)
    • C12Y505/01012—Copalyl diphosphate synthase (5.5.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y505/00—Intramolecular lyases (5.5)
    • C12Y505/01—Intramolecular lyases (5.5.1)
    • C12Y505/01013—Ent-copalyl diphosphate synthase (5.5.1.13)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Definitions

  • the invention relates to the production of one or more terpenoids, including steviol and steviol glycosides, through genetic engineering.
  • Steviol glycosides are natural constituents of the plant Stevia rebaudiana Bertoni, referred to as Stevia.
  • Stevia is native to the Amambay region of Northeastern Paraguay and has been reported to grow in neighboring parts of Brazil and Argentina.
  • Stevia leaves have been used to sweeten beverages and make tea.
  • the leaves are also used for their medicinal benefits in high blood pressure, obesity, topical dressing of wounds and other skin disorders (1).
  • the crushed Stevia leaves are about 30 times sweeter than sugar (2).
  • the sweet tasting components of the Stevia plant are called steviol glycosides.
  • Steviol glycosides are obtained from the leaves of Stevia rebaudiana Bertoni. The leaves are processed with hot water and aqueous extraction to concentrate and purify the steviol glycosides. The final product may be spray dried. Steviol glycosides preparations are available as white or slightly yellowish white crystalline odorless soluble powders.
  • steviol glycoside sweeteners solely relies on cultivation of the plant Stevia and extraction of steviol glycosides from the plant, which yields variable mixtures with undesirable taste profiles, and the yield is severely limited by cultivation and extraction procedures.
  • a promising solution to this problem is to engineer fast growing microorganisms such as bacteria and yeast to synthesize steviol glycosides or its precursor molecule steviol that can be chemically converted to steviol glycosides through established inexpensive methods.
  • aspects of the present invention relate to methods involving recombinantly expressing a copalyl diphosphate synthase (CPS), kaurene synthase (KS) and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in a cell that expresses (or overexpresses one or more components of) an endogenous isopenoid synthesis pathway, such as the non-mevalonate (MEP) pathway or the mevalonic acid pathway (MVA).
  • the cell is a bacterial cell such as an Escherichia coli cell.
  • the bacterial cell is a Gram-positive cell such as a Bacillus cell.
  • the cell is a yeast cell such as a Saccharomyces cell, Pichia cell, or a Yarrowia cell.
  • the cell is an algal cell or a plant cell.
  • the copalyl diphosphate synthase (CPS) enzyme is a Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme.
  • the kaurene synthase (KS) enzyme is a Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme.
  • the GGPPS enzyme is a Taxus enzyme such as a Taxus canadenis enzyme or Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme.
  • the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP pathway is/are expressed from one or more plasmids.
  • the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP pathway is/are incorporated into the genome of the cell.
  • one or more overexpressed components of the non-mevalonate (MEP) pathway are selected from dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB.
  • dxs, idi, ispD and ispF are overexpressed in the cell.
  • dxs, idi, ispD and ispF can be expressed or overexpressed on the operon dxs-idi-iSpDF, or ispC, ispE, ispG and ispH can be expressed or overexpressed on the operon ispC-ispE-ispG-ispH.
  • the gene encoding the copalyl diphosphate synthase (CPS) enzyme, the gene encoding the kaurene synthase (KS) enzyme and the gene encoding the GGPPS enzyme are expressed together on an operon.
  • the operon is KS-CPS-GGPPS.
  • the cell further expresses a kaurene oxidase (KO), a P450 mono- oxygenase, and kaurenoic acid 13-hydroxylase (KAH), a cytochrome P450, or a catalytically active portion thereof.
  • KO kaurene oxidase
  • KAH kaurenoic acid 13-hydroxylase
  • cytochrome P450 or a catalytically active portion thereof.
  • the KO and KAH enzyme or a catalytically active portion thereof is fused to a cytochrome P450 reductase enzyme or a catalytically active portion thereof.
  • the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, and the gene encoding the kaurenoic acid 13-hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion are expressed together on an operon.
  • the operon is KO-KAH.
  • the gene encoding the kaurene oxidase (KO) synthase enzyme, the gene encoding the kaurenoic acid 13-hydroxylase (KAH) enzyme and/or the gene encoding the catalytically active portion thereof fused to a cytochrome P450 reductase enzyme or a catalytically active portion is expressed from one or more plasmids.
  • the gene encoding the kaurene oxidase (KO) synthase enzyme, the gene encoding the kaurenoic acid 13-hydroxylase (KAH) enzyme and/or the gene encoding the catalytically active portion thereof fused to a cytochrome P450 reductase enzyme or a catalytically active portion is incorporated into the genome of the cell.
  • the cell further expresses one or more UDP-glycosyltransferases (UGTs) or a catalytically active portion thereof.
  • the UDP- glycosyltransferase (UGT) enzyme(s) is a Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme.
  • the gene encoding for one or more of the UDP- glycosyltransferases (UGTs) or a catalytically active portion are expressed together on an operon.
  • the gene encoding for the UDP-glycosyltransferases (UGTs) or a catalytically active portion is expressed from one or more plasmids.
  • the gene encoding for the UDP-glycosyltransferases (UGTs) or a catalytically active portion is incorporated into the genome of the cell.
  • the expression of the copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS) enzyme, and the one or more components of the MEP pathway can be balanced to maximize production of kaurene.
  • Methods associated with the invention can further encompass culturing a cell to produce kaurene.
  • the expression of the copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS), kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme, and the one or more components of the MEP pathway, can be balanced to maximize production of steviol.
  • Methods associated with the invention can further encompass culturing a cell to produce steviol.
  • Methods associated with the invention can further comprise recovering the kaurene, steviol or steviol glycosides from the cell culture.
  • the kaurene, steviol and/or steviol glycosides is recovered from the gas phase while in other embodiments, an organic layer or polymeric resin is added to the cell culture, and the kaurene, steviol and/or steviol glycosides is recovered from the organic layer or polymeric resin.
  • the steviol glycoside is selected from rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, and dulcoside A.
  • the terpenoid produced is steviobioside or stevioside.
  • aspects of the invention relate to cells that express or overexpress an endogenous isoprenoid synthesis pathway, such as MEP or MVA (or are engineered to overexpress one or more components of said pathway), and that recombinantly expresses a copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS) enzyme, kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme.
  • CPS copalyl diphosphate synthase
  • KS kaurene synthase
  • GGPPS geranylgeranyl diphosphate synthase
  • KO kaurene oxidase
  • KAH kaurenoic acid 13-hydroxylase
  • the cell is a bacterial cell such as an Escherichia coli cell, and which overexpresses one or more components of the MEP pathway as described in detail herein.
  • the bacterial cell is a Gram-positive cell such as a Bacillus cell.
  • the cell is a yeast cell such as a Saccharomyces cell, Pichia pastoris, or a
  • the cell is an algal cell or a plant cell.
  • aspects of the invention relate to methods for selecting a cell that exhibits enhanced production of kaurene, steviol or steviol glycosides, including creating or obtaining a cell that expresses or overexpresses one or more components of the mevalonic acid pathway (MVA) or non-mevalonate (MEP) pathway, producing kaurene, steviol or steviol glycosides from the cell, comparing the amount of kaurene, steviol or steviol glycosides produced from the cell to the amount of kaurene, steviol or steviol glycosides produced in a control cell, and selecting a first improved cell that produces a higher amount of kaurene, steviol or steviol glycosides than a control cell, wherein a first improved cell that produces a higher amount of kaurene, steviol or steviol glycosides than the control cell is a cell that exhibits enhanced production of kaurene, steviol or steviol glycosides.
  • MVA mevalonic acid pathway
  • MEP non-meval
  • the steviol or steviol glycoside is steviobioside, stevioside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, or dulcoside A.
  • the cell recombinant expresses a copalyl diphosphate synthase (CPS) enzyme and/or a kaurene synthase (KS) enzyme and/or a geranylgeranyl diphosphate synthase (GGPPS) enzyme.
  • CPS copalyl diphosphate synthase
  • KS kaurene synthase
  • GGPPS geranylgeranyl diphosphate synthase
  • Methods can further comprise altering the level of expression of one or more of the components of the non-mevalonate (MEP) pathway, the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme and/or the geranylgeranyl diphosphate synthase (GGPPS) enzyme in the first improved cell to produce a second improved cell, and comparing the amount of kaurene produced from the second improved cell to the amount of kaurene produced in the first improved cell, wherein a second improved cell that produces a higher amount of kaurene than the first improved cell is a cell that exhibits enhanced production of kaurene.
  • MEP non-mevalonate
  • CPS copalyl diphosphate synthase
  • KS kaurene synthase
  • GGPPS geranylgeranyl diphosphate synthase
  • the copalyl diphosphate synthase (CPS) and/or the kaurene synthase (KS) enzyme is a Stevia enzyme, optionally a Stevia rebaudiana Bertoni enzyme.
  • the cell can further recombinantly express any of the polypeptides associated with the invention.
  • aspects of the invention relate to isolated polypeptides comprising a kaurene oxidase (KO) enzyme, kaurenoic acid 13 -hydroxylase (KAH) enzyme or a catalytically active portion of KO or KAH fused to a cytochrome P450 reductase enzyme or a catalytically active portion thereof.
  • the cytochrome P450 reductase enzyme is a Taxus cytochrome P450 reductase (TCPR).
  • the kaurene oxidase (KO) enzyme or kaurenoic acid 13 -hydroxylase (KAH) enzyme and TCPR are joined by a linker such as GSTGS (SEQ ID NO: 15).
  • the kaurene oxidase (KO) enzyme, kaurenoic acid 13- hydroxylase (KAH) enzyme or TCPR are truncated to remove all or part of the transmembrane region.
  • an additional peptide is fused to kaurene oxidase (KO) enzyme and/or kaurenoic acid 13 -hydroxylase (KAH).
  • the additional peptide is from bovine 17a hydroxylase.
  • the peptide is MALLLAVF (SEQ ID NO: 16).
  • aspects of the invention relate to methods for increasing terpenoid production in a cell that produces one or more terpenoids, such as kaurene, steviol or steviol glycosides.
  • the methods include controlling the accumulation of indole in the cell or in a culture of the cells, thereby increasing terpenoid production in a cell.
  • Any of the cells described herein can be used in the methods, including bacterial cells, such as Escherichia coli cells; Gram-positive cells, such as Bacillus cells; yeast cells, such as Saccharomyces cells, Pichia cells, or Yarrowia cells; algal cells; plant cells; and any of the engineered cells described herein.
  • the step of controlling the accumulation of indole in the cell or in a culture of the cells includes balancing the upstream non-mevalonate isoprenoid pathway with the downstream product synthesis pathways and/or modifying or regulating the indole pathway. In other embodiments, the step of controlling the accumulation of indole in the cell or in a culture of the cells includes or further includes removing the accumulated indole from the fermentation through chemical methods, such as by using absorbents or scavengers.
  • aspects of the invention relate to methods that include measuring the amount or concentration of indole in a cell that produces one or more terpenoids, such as kaurene, steviol or steviol glycosides, or in a culture of the cells that produce one or more terpenoids, such as kaurene, steviol or steviol glycosides.
  • the methods can include measuring the amount or concentration of indole two or more times.
  • the measured amount or concentration of indole in the cell or cells is used to guide a process of producing one or more terpenoids.
  • the measured amount or concentration of indole is used to guide strain construction.
  • the invention provides a method for making a product containing a terpenoid selected from kaurene, a steviol, or a steviol glycoside.
  • the method comprises increasing terpenoid production in a cell that produces one or more terpenoids by controlling the accumulation of indole in the cell or in a culture of the cells.
  • the terpenoid is recovered from the cell(s), and optionally, one or more chemical or enzymatic steps may be performed to produce the desired compound.
  • the recovered terpenoid or the terpenoid prepared through one or more chemical or enzymatic steps is incorporated into a product to thereby make the product containing a terpenoid.
  • the product is a food product or beverage.
  • FIG. 1 Biosynthetic scheme for steviol glycoside production. Schematics of the four modules, the native, upstream isoprenoid pathway (steps I to VII), synthetic downstream kaurene (steps VIII to X), steviol (steps XI and XII), and steviol glycoside (bottom panel).
  • steps I to VII the native, upstream isoprenoid pathway
  • steps VIII to X synthetic downstream kaurene
  • steviol steps XI and XII
  • steviol glycoside bottom panel.
  • divergence of the MEP isoprenoid pathway from glycolysis initiates at the precursors glyceraldehyde-3 phosphate (G3P) and pyruvate (PYR) (I- VII).
  • G3P glyceraldehyde-3 phosphate
  • PYR pyruvate
  • the steviol pathway bifurcation starts from the E.
  • coli isoprenoid precursor IPP and DMAPP to the "linear" precursor geranylgeranyl diphosphate (VIII), copalyl diphosphate (CP) (IX), "cyclic” karuene (X), “oxidized” kaurenoic acid (XI), and steviol (XII), followed by multiple rounds of glycosylations to steviol glycosides.
  • the enzymes involved in the biosynthetic pathways from G3P and PYR to steviol glycosides include: DXS-l-deoxy-D-xylulose-5-phosphate synthase, ispC-l-Deoxy-D-xylulose-5-phosphate reductoisomerase, IspD-4-diphosphocytidyl-2C-methyl- D-erythritol synthase, IspE-4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, IspF-2C- Methyl-D-erythritol-2,4-cyclodiphosphate Synthase, IspG- l-hydroxy-2-methyl-2-(E)-butenyl-4- diphosphate synthase, IspH-4-hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate reductase, IDI- is
  • FIG. 2 Schematics of the chemical synthesis of steviol glycosides to rebaudioside A. Specifically a trimethylsilyl (TMS) protected at C19 COOH group of the steviol is synthesized from the microbially derived steviol. Further, tri-glucosylation at C13 -OH position of the steviol is performed using protected -Glc- -Glc(2 ⁇ l)- -Glc(3 ⁇ l) group. This is followed by a deprotection of the TMS and coupling of protected mono ⁇ -Glc-Br moiety. The final deprotection will remove all of the protecting groups to produce rebaudioside A.
  • TMS trimethylsilyl
  • FIG. 3 Multivariate-modular engineering of steviol glycosides.
  • A Modularization of rebaudioside D (Reb D) biosynthetic pathway.
  • B Schematics of the modular pathway and the production of committed cyclic diterpenoid precursor kaurene from the engineered E. coli strains. Experimentation with four strains on a small upstream and downstream expression profile showed significant differences in kaurene production between strains, with one E. coli strain showing production of 45 mg/L.
  • FIG. 4 Correlation between indole accumulation and kaurene production.
  • the GC chromato graph of the two strains show low (ChlT7MEP-p20TrcKCG) and high (ChlTrcMEP-p5T7KCG) accumulation of kaurene.
  • the peak 1 and 2 corresponds to indole and kaurene respectively.
  • the corresponding MS spectra are shown in the right.
  • Steviol glycosides are of recent immense interest to the food and beverages industry due to their intense sweetening properties and as a potential alternative to synthetic sweeteners. Stevia leaves accumulate a mixture of at least eight steviol glycosides.
  • Reb A is a high value chemical in the multibillion dollar F&B industry. Developing a sustainable and economical production process for Reb A not only has commercial interest but also potential health implications, due to the extensive history of use as a natural herbal sweetener and medicine.
  • the diversity of various steviol glycosides results from the differences in the glycosylation on the diterpenoid skeleton, steviol, which primarily determines the sweetening property of these molecules.
  • Stevioside is the main sweetening compound found in the Stevia leaf (2- 10%), followed by Reb A (-1-3%) (1). Stevioside and Reb A were tested for stability in carbonated beverages and found to be both heat and pH stable.
  • Stevia extract The sweetening properties of Stevia extract are derived from stevioside and Reb A molecules.
  • Stevioside is reported to be 143 times sweeter than sucrose on a weight basis and Reb A is 242 times sweeter (1).
  • the taste quality of Reb A is better than stevioside, because it is sweeter and less bitter.
  • the taste "quality” is determined by the percentage composition of stevioside and Reb A. If stevioside is more than 50%, the taste is "common/traditional” with a "licorice” aftertaste, whereas if Reb A is more than 50%, the taste is improved with a reduced aftertaste (2).
  • Reb A steviol glycosides is important for its use as sweeteners.
  • Steviol glycosides are diterpenoids and the early biosynthetic pathway until GGPP share common intermediates with other diterpenoid such as Taxol biosynthetic pathway (8).
  • the overall pathway is modularized into parts: 1) the formation of starting precursor IPP and DMAPP from the central carbon metabolites glyceraldehydes-3-phosphate and pyruvate (Figure 1, blue structures); 2) the production of the first dedicated intermediate, kaurene (Figure 1, red structures); 3) biosynthesis of the key intermediate, steviol ( Figure 1, gray structures); and 4) the formation various steviol glycosides (Figure 1, black structures).
  • IPP and DMAPP can be derived from two biosynthetic routes, the MVA and MEP pathway.
  • the first step in the diterpenoid steviol biosynthesis is conversion of IPP and DMAPP into GGPP.
  • GGPP is the four subunit precursor for all diterpenoid molecules.
  • CDP protonation-initiated cyclization to copalyl diphosphate
  • Kaurene is then produced from CDP by an ionization dependant cyclization catalysed by kaurene synthase (KS).
  • Kaurene is then oxidized in a three step reaction to kaurenoic acid, by kaurene oxidase (KO) a P450 mono-oxygenase.
  • KO kaurene oxidase
  • kaurene to kaurenoic acid.
  • the next step in the pathway is the hydroxylation of kaurenoic acid by kaurenoic acid 13 -hydroxylase (KAH).
  • KAH kaurenoic acid 13 -hydroxylase
  • Aglycone steviol has two hydroxyl groups, one attached to the C- 19 of the C-4 carboxyl and the other attached to the C-13, both of which in theory can be glycosylated using UDP- glycosyltransferases (UGTs) (10).
  • UDP- glycosyltransferases UDP- glycosyltransferases
  • Stevioside is then produced by the glycosylation of the C-19 carboxyl of steviolbioside.
  • In vitro studies on various substrates shows that C-19 is glucosylated after the glucosylation of the C2' of the C13-glucose of steviolmonoside.
  • Reb A is then synthesized by glucosylation of the C-3' of the C-13-O-glucose. Further, no product was observed using Reb A as a substrate, indicating it is the terminal step in the pathway.
  • the tri-glycoside stevioside and the tetra-glycoside Reb A typically represent the majority of the steviol glycosides present in Stevia leaves.
  • rhamnosylated glycosides can also be formed by addition of a UDP rhamnose moiety to steviolmonoside, and in genotypes enriched in Reb A C, the C2' of the C13-glucose can be xylosylated to form rebaudioside F.
  • the metabolic pathway for steviol glycosides consists of an upstream isoprenoid pathway that is native to E. coli and a heterologous downstream terpenoid pathway (Fig. 1).
  • the upstream mevalonic acid (MVA) pathway in certain microbial organisms such as yeast or methylerythritol phosphate (MEP) pathway in certain microbial organisms such as E. coli can produce the two common building blocks, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), from which isoprenoid compounds are formed (7).
  • Microbial production of terpenoids such as kaurene and steviol is demonstrated herein. When expressed at satisfactory levels, microbial routes reduce dramatically the cost of production of such compounds.
  • the upstream pathway involves production of isopentyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which can be achieved by two different metabolic pathways: the mevalonic acid (MVA) pathway and the MEP (2-C-methyl-D-erythritol 4-phosphate) pathway, also called the MEP/DOXP (2-C-methyl-D-erythritol 4-phosphate/l- deoxy-D-xylulose 5-phosphate) pathway, the non-mevalonate pathway or the mevalonic acid- independent pathway.
  • MUA mevalonic acid
  • MEP 2-C-methyl-D-erythritol 4-phosphate
  • MEP/DOXP 2-C-methyl-D-erythritol 4-phosphate/l- deoxy-D-xylulose 5-phosphate
  • the downstream pathway is a synthetic pathway that leads to production of a terpenoids and involves recombinant gene expression of a terpenoid synthase (also referred to as terpene cyclase) enzyme, and a geranylgeranyl diphosphate synthase (GGPPS) enzyme.
  • a terpenoid synthase enzyme is a diterpenoid synthase enzyme.
  • diterpenoid synthase enzymes include copalyl diphosphate synthase (CPS) and kaurene synthase (KS).
  • downstream pathways described herein is not a simple linear or additive process. Rather, through complex combinatorial analysis, optimization is achieved through balancing
  • a gene within the MEP pathway is one of the following: dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA or ispB.
  • Expression of one or more genes and/or proteins within the MEP pathway can be upregulated and/or downregulated.
  • upregulation of one or more genes and/or proteins within the MEP pathway can be combined with downregulation of one or more genes and/or proteins within the MEP pathway.
  • genes and/or proteins can be regulated alone or in combination.
  • the expression of dxs can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB.
  • the expression of ispC can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB.
  • the expression of ispD can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispE, ispF, ispG, ispH, idi, ispA and ispB.
  • the expression of ispE can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispF, ispG, ispH, idi, ispA and ispB.
  • the expression of ispF can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispG, ispH, idi, ispA and ispB.
  • the expression of ispG can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispH, idi, ispA and ispB.
  • ispH can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, idi, ispA and ispB.
  • idi can be upregulated or downregulated alone or in combination with
  • the expression of ispA can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi and ispB.
  • the expression of ispB can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi and ispA.
  • expression of the gene and/or protein of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, and idi is upregulated while expression of the gene and/or protein of ispA and/or ispB is downregulated.
  • Expression of genes within the MEP pathway can be regulated in a modular method. As used herein, regulation by a modular method refers to regulation of multiple genes together. For example, in some embodiments, multiple genes within the MEP pathway are recombinantly expressed on a contiguous region of DNA, such as an operon. It should be appreciated that a cell that expresses such a module can also express one or more other genes within the MEP pathway either recombinantly or endogenously.
  • modules of genes within the MEP pathway is a module containing the genes dxs, idi, ispD and ispF, referred to herein as dxs-idi-ispDF. It should be appreciated that modules of genes within the MEP pathway, consistent with aspects of the invention, can contain any of the genes within the MEP pathway, in any order.
  • the synthetic downstream terpenoid synthesis pathway involves recombinant expression of a terpenoid synthase enzyme and a GGPPS enzyme. Any terpenoid synthase enzyme, as discussed above, can be expressed with GGPPS depending on the downstream product to be produced. For example, CPS and KS is used for the production of kaurene. Recombinant expression of the CPS and KS enzyme and the GGPPS enzyme can be regulated independently or together. In some embodiments the three enzymes are regulated together in a modular fashion.
  • the three enzymes can be expressed in an operon in any order (e.g., GGPPS-CPS-KS, referred to as "GCK,” or KS-CPS-GGPPS, referred to as “KCG” or KS-GGPPS-CPS, referred to as “KGC” or GGPPS-KS-CPS, referred to as "GKC”).
  • GGPPS-CPS-KS referred to as "GCK”
  • KCG KS-CPS-GGPPS
  • KGC GGPPS-KS-CPS-CPS
  • GKC GGPPS-KS-CPS
  • the synthetic downstream steviol synthesis pathway also involves recombinant expression of P450 mono-oxygenases such as kaurene oxidase (KO) and kaurenoic acid 13- hydroxylase (KAH) enzyme.
  • P450 mono-oxygenases such as kaurene oxidase (KO) and kaurenoic acid 13- hydroxylase (KAH) enzyme.
  • Any P450 mono-oxygenases can be expressed with CPS and KS synthase enzyme and the GGPPS enzyme on the downstream product to be produced.
  • kaurene oxidase (KO) and kaurenoic acid 13 -hydroxylase (KAH) enzyme are used for the production of steviol from kaurene.
  • Recombinant expression of the kaurene oxidase (KO) and kaurenoic acid 13 -hydroxylase (KAH) enzyme and/or a gene encoding for a catalytically active portion thereof is fused to a cytochrome P450 reductase enzyme (CPR) (to form KOCPR and KAHCPR fusions) or a catalytically active portion can be regulated independently or together.
  • CPR cytochrome P450 reductase enzyme
  • these two enzymes are regulated together in a modular fashion.
  • the two enzymes can be expressed in an operon in either order (KOCPR-KAHCPR, or KAHCPR-KOCPR).
  • Manipulation of the expression of genes and/or proteins can be achieved through various methods.
  • expression of the genes or operons can be regulated through selection of promoters, such as inducible promoters, with different strengths.
  • promoters include Trc, T5 and T7.
  • expression of genes or operons can be regulated through manipulation of the copy number of the gene or operon in the cell.
  • a strain containing an additional copy of the dxs-idi-ispDF operon on its chromosome under Trc promoter control produces an increased amount of taxadiene relative to one overexpressing only the synthetic downstream pathway.
  • expression of genes or operons can be regulated through manipulating the order of the genes within a module. For example, in certain embodiments, changing the order of the genes in a downstream synthetic operon from GCK to KCG or KGC or GKC and KOCPR-KAHCPR to KAHCPR-KOCPR results in an increase in steviol production.
  • expression of genes or operons is regulated through integration of one or more genes or operons into a chromosome. For example, in certain embodiments, integration of the upstream dxs-idi-ispDF operon into the chromosome of a cell results in increased
  • the dxs-idi-ispD-ispF operon and the K-C-G operon are controlled by the same promoter, such as the T7 promoter, or promoters of similar strength.
  • the genes associated with the invention can be obtained from a variety of sources.
  • the genes within the MEP pathway are bacterial genes such as Escherichia coli genes.
  • the gene encoding for GGPPS is a plant gene.
  • the gene encoding for GGPPS can be from a species of Taxus such as Taxus canadensis (T. canadensis) or Stevia such as Stevia rebaudiana Bertoni.
  • the gene encoding for CPS and/or KS synthase is a plant gene.
  • the gene encoding for CPS and KS synthase can be from a species of Stevia such as Stevia rebaudiana Bertoni.
  • GenBank Accession numbers for T. canadensis GGPPS, Stevia rebaudiana GGPPS, CPS and KS are provided by AF081514, ABD92926, AAB87091, and AF097311_1 respectively, the sequences of which are incorporated by reference herein in their entireties.
  • Exemplary protein sequences for a number of the enzymes described herein are provided in Table 2.
  • homologous genes for use in methods associated with the invention can be obtained from other species and can be identified by homology searches, for example through a protein BLAST search, available at the National Center for Biotechnology Information (NCBI) internet site (www.ncbi.nlm.nih.gov).
  • Genes and/or operons associated with the invention can be cloned, for example by PCR amplification and/or restriction digestion, from DNA from any source of DNA which contains the given gene.
  • a gene and/or operon associated with the invention is synthetic. Any means of obtaining a gene and/or operon associated with the invention is compatible with the instant invention.
  • the GGPPS enzyme has one or more of the follow mutations: A162V, G140C, L182M, F218Y, D160G, C184S, K367R, A151T, M185I, D264Y, E368D, C184R, L331I, G262V, R365S, A114D, S239C, G295D, I276V, K343N, P183S, I172T, D267G, I149V, T234I, E153D and T259A (wherein the numbering refers to amino acids of T.
  • the GGPPS enzyme has a mutation in residue S239 and/or residue G295. In certain embodiments, the GGPPS enzyme has the mutation S239C and/or G295D.
  • modification of a gene before it is recombinantly expressed in a cell involves codon optimization for expression in a bacterial cell.
  • Codon usages for a variety of organisms can be accessed in the Codon Usage Database (www.kazusa.or.jp/codon/). Codon optimization, including identification of optimal codons for a variety of organisms, and methods for achieving codon optimization, are familiar to one of ordinary skill in the art, and can be achieved using standard methods.
  • modifying a gene before it is recombinantly expressed in a cell involves making one or more mutations in the gene before it is recombinantly expressed in a cell.
  • a mutation can involve a substitution or deletion of a single nucleotide or multiple nucleotides.
  • a mutation of one or more nucleotides in a gene will result in a mutation in the protein produced from the gene, such as a substitution or deletion of one or more amino acids.
  • modifications are made using standard molecular biology methods well known in the art.
  • a cell that has been optimized for production of a terpenoid may be advantageous to use.
  • a cell that overexpresses one or more components of the non-mevalonate (MEP) pathway is used, at least in part, to amplify isopentyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), substrates of GGPPS.
  • overexpression of one or more components of the non-mevalonate (MEP) pathway is achieved by increasing the copy number of one or more components of the non- mevalonate (MEP) pathway.
  • copy numbers of components at rate-limiting steps in the MEP pathway such as (dxs, ispD, ispF, idi) can be amplified, such as by additional episomal expression.
  • rational design is involved in constructing specific mutations in proteins such as enzymes.
  • “rational design” refers to incorporating knowledge of the enzyme, or related enzymes, such as its three dimensional structure, its active site(s), its substrate(s) and/or the interaction between the enzyme and substrate, into the design of the specific mutation. Based on a rational design approach, mutations can be created in an enzyme which can then be screened for increased production of a terpenoid relative to control levels. In some embodiments, mutations can be rationally designed based on homology modeling. As used herein, “homology modeling” refers to the process of constructing an atomic resolution model of one protein from its amino acid sequence and a three-dimensional structure of a related homologous protein.
  • random mutations can be made in a gene, such as a gene encoding for an enzyme, and these mutations can be screened for increased production of a product, such as a terpenoid and/or steviol glycoside, relative to control levels.
  • screening for mutations in components of the MEP pathway, or components of other pathways, that lead to enhanced production of a product, such as a terpenoid and/or steviol glycoside may be conducted through a random mutagenesis screen, or through screening of known mutations.
  • shotgun cloning of genomic fragments could be used to identify genomic regions that lead to an increase in production of a product, such as a terpenoid and/or steviol glycoside, through screening cells or organisms that have these fragments for increased production of a terpenoid. In some cases one or more mutations may be combined in the same cell or organism.
  • production of a product, such as a terpenoid and/or steviol glycoside in a cell can be increased through manipulation of enzymes that act in the same pathway as the enzymes associated with the invention.
  • optimization of protein expression can also be achieved through selection of appropriate promoters and ribosome binding sites. In some embodiments, this may include the selection of high-copy number plasmids, or low or medium-copy number plasmids.
  • the step of transcription termination can also be targeted for regulation of gene expression, through the introduction or elimination of structures such as stem-loops.
  • the invention encompasses any type of cell that recombinantly expresses genes associated with the invention, including prokaryotic and eukaryotic cells.
  • the cell is a bacterial cell, such as Escherichia spp., Streptomyces spp., Zymonas spp., Acetobacter spp., Citrobacter spp., Synechocystis spp., Rhizobium spp., Clostridium spp., Corynebacterium spp., Streptococcus spp., Xanthomonas spp., Lactobacillus spp., Lactococcus spp., Bacillus spp., Alcaligenes spp., Pseudomonas spp., Aeromonas spp., Azotobacter spp., Comamon
  • the bacterial cell can be a Gram- negative cell such as an Escherichia coli (E. coli) cell, or a Gram-positive cell such as a species of Bacillus.
  • E. coli Escherichia coli
  • the cell is a fungal cell such as a yeast cell, e.g., Saccharomyces spp., Schizosaccharomyces spp., Pichia spp., Paffia spp., Kluyveromyces spp., Candida spp., Talaromyces spp., Brettanomyces spp., Pachysolen spp., Debaryomyces spp., Yarrowia spp., and industrial polyploid yeast strains.
  • yeast strain is a S. cerevisiae strain or a Yarrowia spp. strain.
  • the cell is an algal cell, or a plant cell. It should be appreciated that some cells compatible with the invention may express an endogenous copy of one or more of the genes associated with the MEP and/or MVA pathways as well as a recombinant copy.
  • a cell may endogenously express one or more enzymes from the pathways described herein and may recombinantly express one or more other enzymes from the pathways described herein for efficient production of a product, such as a terpenoid and/or steviol glycoside.
  • Further aspects of the invention relate to screening for bacterial cells or strains that exhibit optimized production of a product, such as a terpenoid and/or steviol glycoside.
  • methods associated with the invention involve generating cells that
  • Terpenoid production from culturing of such cells can be measured and compared to a control cell wherein a cell that exhibits a higher amount of production of product, such as a terpenoid and/or steviol glycoside, relative to a control cell is selected as a first improved cell.
  • the cell can be further modified by recombinant expression of a terpenoid synthase enzyme and a GGPPS enzyme.
  • the level of expression of one or more of the components of the non-mevalonate (MEP) pathway, the terpenoid synthase enzyme and/or the GGPPS enzyme in the cell can then be manipulated and terpenoid and/or steviol glycoside production can be measured again, leading to selection of a second improved cell that produces greater amounts of product, such as a terpenoid and/or steviol glycoside, than the first improved cell.
  • the terpenoid synthase enzyme is a CPS and/or KS enzymes.
  • the metabolite indole anti-cor relates as a direct variable to the diterpenoid production in engineered strains. Further controlling the accumulation of indole for improving the flux towards terpenoid biosynthesis in bacterial systems (specifically in cells, such as E. coli cells) or other cells, can be achieved by balancing the upstream non-mevalonate isoprenoid pathway with the downstream product synthesis pathways or by modifications to or regulation of the indole pathway. In so doing, the skilled person can reduce or control the accumulation of indole and thereby reduce the inhibitory effect of indole on the production of steviol and steviol glycosides. Other methods for reducing or controlling the accumulation of indole include removing the accumulated indole from the fermentation through chemical methods such as by using absorbents, scavengers, etc.
  • methods include measuring the amount or concentration of indole in a cell that produces one or more terpenoids or in a culture of the cells that produce one or more terpenoids.
  • the amount or concentration of indole can be measured once, or two or more times, as suitable, using methods known in the art and as described herein. Such methods can be used to guide processes of producing one or more terpenoids, e.g., in process improvement. Such methods can be used to guide strain construction, e.g., for strain improvement.
  • cytochrome P450 Functional expression of plant cytochrome P450 has been considered challenging due to the inherent limitations of bacterial platforms, such as the absence of electron transfer machinery, cytochrome P450 reductases, and translational incompatibility of the membrane signal modules of P450 enzymes due to the lack of an endoplasmic reticulum.
  • the KO and KAH associated with methods of the invention is optimized through N-terminal transmembrane engineering and/or the generation of chimeric enzymes through translational fusion with a CPR redox partner.
  • the CPR redox partner is a Stevia cytochrome P450 reductase.
  • the gene encoding for KO and KAH synthase can be from a species of Stevia such as Stevia rebaudiana Bertoni. Representative GenBank Accession numbers for Stevia rebaudiana KO and KAH are provided by ABA42921 and ACD93722, the sequence of which is incorporated by reference herein).
  • Stevia NADPH: cytochrome P450 reductase (SCPR) is obtained from Stevia rebaudiana Bertoni (GenBank Accession number ABB88839, the sequence of which is incorporated by reference herein).
  • KO, KAH and TCPR can be joined by a linker such as GSTGS (SEQ ID NO: 15).
  • KO, KAH, TCPR and/or SCPR are truncated to remove all or part of the transmembrane region of one or both proteins.
  • An additional peptide can also be fused to KO and KAH.
  • one or more amino acids from bovine 17a hydroxylase can be added to KO and KAH.
  • the peptide MALLLAVF (SEQ ID NO: 16) is added to KO and KAH.
  • a chimeric enzyme constructed from the KO and SCPR is capable of carrying out the first oxidation step kaurene conversion to kaurenoic acid.
  • a chimeric enzyme constructed from KAH and SCPR is capable of carrying out the hydroxylation step kaurenoic acid to steviol.
  • UGTs UDP-glycosyltransferases
  • the UGTs associated with methods of the invention are optimized through N-terminal transmembrane engineering and/or the generation of chimeric enzymes through domain swapping with other plant UGTs.
  • the gene encoding for plant UGTs for the synthesis of steviol glycosides can be from a species of Stevia such as Stevia rebaudiana Bertoni.
  • GenBank Accession numbers for Stevia rebaudiana UGTS are provided by AAM53963, AAR06921, AAR06920, AAR06917, AAN40684, and ACE87855, the sequences of which is incorporated by reference herein.
  • a chimeric enzyme constructed from the UGTs is capable of carrying out the first glucosylation step steviol to steviolmonoside. In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the glucosylation of the C-20 of the 13-O-glucose of steviolmonoside, which results in the production of steviolbioside. In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the glucosylation of the glycosylation of the C-19 carboxyl of steviolbioside, which results in the production of Stevioside. In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the glucosylation of the C-3' of the C- 13-O-glucose, which results in the production of Rebaudioside A (Reb A).
  • At least one enzymatic step such as one or more glycosylation steps, are performed ex vivo.
  • polypeptide As used herein, the terms “protein” and “polypeptide” are used interchangeably and thus the term polypeptide may be used to refer to a full-length polypeptide and may also be used to refer to a fragment of a full-length polypeptide.
  • isolated means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure.
  • substantially pure means that the proteins or polypeptides are essentially free of other substances with which they may be found in production, nature, or in vivo systems to an extent practical and appropriate for their intended use.
  • substantially pure polypeptides may be obtained naturally or produced using methods described herein and may be purified with techniques well known in the art. Because an isolated protein may be admixed with other components in a preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e.
  • the invention also encompasses nucleic acids that encode for any of the polypeptides described herein, libraries that contain any of the nucleic acids and/or polypeptides described herein, and compositions that contain any of the nucleic acids and/or polypeptides described herein.
  • one or more of the genes associated with the invention is expressed in a recombinant expression vector.
  • a "vector" may be any of a number of nucleic acids into which a desired sequence or sequences may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell.
  • Vectors are typically composed of DNA, although RNA vectors are also available.
  • Vectors include, but are not limited to: plasmids, fosmids, phagemids, virus genomes and artificial chromosomes.
  • a cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell.
  • replication of the desired sequence may occur many times as the plasmid increases in copy number within the host cell such as a host bacterium or just a single time per host before the host reproduces by mitosis.
  • replication may occur actively during a lytic phase or passively during a lysogenic phase.
  • An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript.
  • Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector.
  • Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., ⁇ -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein).
  • Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.
  • a coding sequence and regulatory sequences are said to be "operably” joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences.
  • two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame- shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.
  • a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript can be translated into the desired protein or polypeptide.
  • nucleic acid molecule that encodes any of the enzymes of the claimed invention is expressed in a cell, a variety of transcription control sequences (e.g.,
  • promoter/enhancer sequences can be used to direct its expression.
  • the promoter can be a native promoter, i.e., the promoter of the gene in its endogenous context, which provides normal regulation of expression of the gene.
  • the promoter can be constitutive, i.e., the promoter is unregulated allowing for continual transcription of its associated gene.
  • conditional promoters also can be used, such as promoters controlled by the presence or absence of a molecule.
  • regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like.
  • 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.
  • Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired.
  • the vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.
  • heterologous DNA 14
  • That heterologous DNA (14) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.
  • Heterologous expression of genes associated with the invention, for production of a terpenoid, such as taxadiene, is demonstrated in the Examples section using E. coli.
  • the novel method for producing terpenoids can also be expressed in other bacterial cells, fungi (including yeast cells), plant cells, etc.
  • a nucleic acid molecule that encodes an enzyme associated with the invention can be introduced into a cell or cells using methods and techniques that are standard in the art.
  • nucleic acid molecules can be introduced by standard protocols such as transformation including chemical transformation and electroporation, transduction, particle bombardment, etc.
  • Expressing the nucleic acid molecule encoding the enzymes of the claimed invention also may be accomplished by integrating the nucleic acid molecule into the genome.
  • one or more genes associated with the invention is expressed recombinantly in a bacterial and yeast cell.
  • Bacterial and yeast cells according to the invention can be cultured in media of any type (rich or minimal) and any composition. As would be understood by one of ordinary skill in the art, routine optimization would allow for use of a variety of types of media.
  • the selected medium can be supplemented with various additional components. Some non-limiting examples of supplemental components include glucose, antibiotics, IPTG for gene induction, ATCC Trace Mineral Supplement, and glycolate.
  • pH and temperature are non- limiting examples of factors which can be optimized.
  • factors such as choice of media, media supplements, and temperature can influence production levels of a product, such as a terpenoid and/or steviol glycoside,.
  • concentration and amount of a supplemental component may be optimized.
  • how often the media is supplemented with one or more supplemental components, and the amount of time that the media is cultured before harvesting a product, such as a terpenoid and/or steviol glycoside can be optimized.
  • the liquid cultures used to grow cells associated with the invention can be housed in any of the culture vessels known and used in the art.
  • large scale production in an aerated reaction vessel such as a stirred tank reactor can be used to produce large quantities of product, such as a terpenoid and/or steviol glycoside, that can be recovered from the cell culture.
  • the terpenoid is recovered from the gas phase of the cell culture, for example by adding an organic layer such as dodecane to the cell culture and recovering the terpenoid from the organic layer.
  • the terpenoid is recovered from the of the cell culture, for example by adding a polymeric resin to the cell culture and recovering the terpenoid from the polymer by solvent extraction.
  • the invention also encompasses the chemical synthesis for the conversion of microbially produced steviol to steviol glycosides (Figure 2).
  • the diterpenoid steviol can be converted to stevioside and rebaudioside A using multi-step chemical assembly of sugar moiety into steviol backbone. More specifically the chemical synthesis consists of following steps, as shown in Figure 2.
  • a trimethylsilyl (TMS) protected at C19 COOH group of the steviol is synthesized from the microbially derived steviol.
  • Tri-glucosylation at the C13-OH position of the steviol is performed using protected -Glc- -Glc(2 ⁇ l)- -Glc(3 ⁇ l) group.
  • TMS trimethylsilyl
  • TMS trimethylsilyl
  • Tri-glucosylation at the C13-OH position of the steviol is performed using protected -Glc- -Glc(2 ⁇ l)- -Glc(3 ⁇ l)
  • the invention involves making a product containing a terpenoid selected from kaurene, a steviol, or a steviol glycoside.
  • the method comprises increasing terpenoid production in a cell that produces one or more terpenoids by controlling the accumulation of indole in the cell or in a culture of the cells, and then recovering the terpenoid from the cell.
  • the cell expresses an endogenous MVA or MEP pathway, and may overexpress one or more components of said pathway as described herein, to maximize production of kaurene, steviol, or steviol glycoside.
  • the method may further comprise conducting one or more chemical or enzymatic steps on the recovered terpenoid to produce a derivative of the terpenoid.
  • the cell is a bacterial cell such as E. coli or B. subtilis, or other cell disclosed herein, including yeast (e.g., Saccharomyces or Pichia pastoris), algal and plant cells.
  • yeast e.g., Saccharomyces or Pichia pastoris
  • the step of controlling the accumulation of indole in the cell or in a culture of the cells may be conducted through strain construction, and/or physically during culture as described herein.
  • the cell may be constructed to express functional components of an "upstream” MEP pathway, and one or more components of a "downstream" terpenoid synthesis pathway.
  • the upstream and downstream pathways may be balanced to control indole accumulation, using a variety of genetic tools, including but not limited to selecting a gene copy number for one or more upstream or downstream pathway enzymes; increasing or decreasing the expression level of the upstream and downstream pathway genes (as individual genes or as operons) using promoters with different or similar strengths and/or modifications to ribosomal binding sites; replacing native genes in the downstream or upstream pathway with heterologous genes coding for homologous enzymes; codon-optimization of one or more heterologous enzymes in the upstream or downstream pathway; amino acid mutations in one or more genes of the downstream and/or upstream pathway; and modifying the order of upstream and downstream pathway genes in a heterologous operon.
  • the cell comprises at least one additional copy of at least one of dxs, idi, ispD, and ispF, which in some embodiments is a heterologous dxs-idi-ispDF operon.
  • the accumulation of indole can be a proxy for the efficiency of terpenoid production, and thus the genetic elements may provide for accumulation of indole in the culture at less than 100 mg/L, or in other embodiments at less than 50 mg/L, at less than 10 mg/L, or at less than 1 mg/L.
  • accumulation of indole in the cell or in a culture of the cells is controlled by modifying or regulating the indole pathway, or by removing the accumulated indole from the cell culture through chemical methods, including the use of one or more absorbents or scavengers.
  • the amount of indole in the culture is continuously or intermittently monitored.
  • the terpenoid is one or more of steviobioside, stevioside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, and dulcoside A, which may be produced in accordance with pathways described herein.
  • the pathway is constructed at least in-part in a microbial system, employing an upstream MEP pathway, and at least one, two, or three or more components of a downstream terpenoid synthesis pathway.
  • the cell may express a copalyl diphosphate synthase (CPS) enzyme, a kaurene synthase (KS) enzyme, and a GGPPS enzyme.
  • the cell may further express a kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme.
  • the cell expresses one or more UDP- glycosyltransferases (UGTs) or a catalytically active portion(s) thereof.
  • Exemplary UGTs include UDP-glycosyltransferase (UGT) enzyme(s) from Stevia (e.g. Stevia rebaudiana
  • the UGTs may be expressed from a plasmid or integrated into the host genome.
  • glycosyltransferase steps may take place ex vivo after recovery of the terpenoid substrate from cells.
  • the terpenoid produced by the method is incorporated into a product, such as a food product or beverage, where the terpenoid is a taste enhancer or bitter blocker.
  • exemplary products include dessert, yogurt, confectionary, sauce, pickle, delicacy, sweet corn, bread, biscuit, or soft drink.
  • Other products include carbonated or non-carbonated drinks (including low-calorie beverages), cordials, milk, soy, mineral drink, canned fruit, jam, juice, ice cream, dietary product (e.g., low calorie products packaged for weight loss or weight control), cake, biscuit, pastry, dessert, sugar free beer, alcoholic beverage, topping, sauce, chutney, spread, cereal, muesli bar, and confectionaries.
  • E coli K12MG1655 A(recA,endA) and E coli K 12MG 1655A(recA,endA)ED3 strains were used as the host strain of karuene strain construction.
  • the sequences of geranylgeranyl pyrophosphate synthase (GGPPS ⁇ Copalyl pyrophosphate synthase (C), and Karuene Synthase (K) were obtained from Taxus canadensis and Stevia rebaudiana (Genbank accession codes: AF081514, AAB87091 and AF097311). Genes were custom- synthesized (from a commercial vendor) to incorporate E. coli translation codon and removal of restriction sites for cloning purposes.
  • dxs-idi-ispDF operon was initially constructed by cloning each of the genes from the genome of E coli K12 MG1655 using the primers dxs(s), dxs(a), idi(s), idi(a), ispDF(s) and ispDFI(a) under pET21C+ plasmid with T7 promoter (p20T7MEP).
  • dxsidiispDFNcol (s) and dxsidiispDFKpnl(a) dxs-idi-ispDF operon was sub-cloned into pTrcHis2B (Invitrogen) plasmid after digestion with Ncol and Kpnl for pTrcMEP plasmid (p20TrcMEP).
  • p20TrcMEP plasmid digested with Mlul and Pmel and cloned into Mlul and Pmel digested p ACYC 184-melA(P2A) plasmid to construct p 1 OTrcMEP plasmid.
  • the downstream kaurene pathway was constructed by cloning PCR fragments of
  • KS, CPS and GGPPS into the Ncol - Xhol, Xhol - EcoRl and EcoRl - Sail sites of pTrcHIS2B plasmid to create p20TrcKCG using the primers KSNcoI(s), KSXhoI(a), CPSXhoI(s),
  • p5T7KCG was constructed by subcloning the Ncol/Sall digested KCG operon from p20TrcKCG into Ncol/Sall digested pCL1920T7 plasmid.
  • the amplified DNA was digested with Xhol/Scal and cloned into the Xhol/Scal digested p20T7MEP plasmid (p20T7MEPKmFRP).
  • p20TrcMEP plasmid was digested with Sacl/Scal and the amplified DNA using the primers KmFRPSacI(s) and KmFRPScal(a) was digested, cloned into the p20TrcMEP plasmid
  • the MEP pathways constructed under the promoters T7 and Trc were localized to the ara operon region in the chromosome with the Kan marker.
  • the PCR fragments were amplified from p20T7MEPKmFRP and p20TrcMEPKm-FRP using the primers IntT7T5(s), IntTrc(s) and Int(a) and then electroporated into E. coli MG1655 recA-end- and E. coli MG1655 recA-end- EDE3 cells for chromosomal integration through the ⁇ Red recombination technique.
  • the site specific localization was confirmed and the Km marker was removed through the action of the FLP recombinase after successful gene integration. Culture growth for screening the kaurene production
  • these preinnoculum were used to seed fresh 2-mL defined feed medium containing 0.5% yeast extract and 20% (v/v) dodecane (13.3 g/L ⁇ 2 ⁇ 0 4 , 4 g/L (NH 4 ) 2 HP0 4 , 1.7 g/L citric acid, 0.0084 g/L EDTA, 0.0025 g/L CoCl 2 , 0.015 g/L MnCl 2 , 0.0015 g/L CuCl 2 , 0.003 g/L H 3 B0 3 , 0.0025 g/L Na 2 Mo0 4 , 0.008 g/L Zn(CH 3 COO) 2 , 0.06 g/L Fe(III) citrate, 0.0045 g/L thiamine, 1.3 g/L MgS0 4 , 10 g/L glycerol, 5 g/L yeast extract, pH 7.0). The culture was maintained with appropriate antibiotics and 100
  • the oven temperature was first kept constant at 50 °C for 1 min, and then increased to 220 °C at the increment of 10 °C/min, and finally held at this temperature for 10 min.
  • the injector and transfer line temperatures were set at 200 °C and 250 °C, respectively. Pure taxadiene was used as a standard for the quantitative measurement of kaurene production from engineered strains.
  • Example 1 Engineering Karuene biosynthesis in E. coli.
  • the upstream MEP pathway module dxs-idi-ispdF, was cloned under the control of two synthetic promoters with low (Trc) and high (T7) strength.
  • the MEP pathway is further localized into the chromosome of the E. coli MG1655 recA-EndA- strain for the overproduction of the upstream isoprenoid metabolites and downstream kaurene.
  • the putative downstream pathway for the biosynthesis of kaurene was cloned under two promoters (Trc and T7) using a 20 copy (p20Trc-KCG) and 5 copy plasmid (p5T7-KCG).
  • the downstream pathways was transferred into the upstream chromosomal MEP pathway engineered strains. A total of 4 strains were constructed with varying upstream and downstream pathway to understand the variation in kaurene production corresponding to the pathway strengths.
  • Fig. 3B summarizes the details of strain construction and results of kaurene accumulation from engineered E. coli strains.
  • the balancing of the upstream and downstream pathway is key for the high accumulation of kaurene. This is the first example of microbial production of the steviol glycoside precursor scaffold kaurene.
  • Example 2 Metabolite Indole accumulation inversely correlates with karuene.
  • Metabolomic analysis of the engineered strains identified the accumulation of the metabolite indole that correlated strongly with pathway expression levels and kaurene production (Fig. 4).
  • the corresponding peaks in the gas chromatography- mass spectrometry (GC-MS) chromatogram was identified as indole and kaurene.
  • Enzyme sequences in accordance with aspects of the invention may be as defined below.
  • the enzymes may be optimized through processes and parameters as described herein, and generally producing amino acid sequences that are at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequences shown below, including with respect to the full length sequence or a catalytically active truncated sequence.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physiology (AREA)

Abstract

The invention relates to recombinant expression of a steviol or steviol glycosides biosynthetic pathway enzymes in cells and the production of steviol or steviol glycosides.

Description

MICROBIAL PRODUCTION OF NATURAL SWEETENERS, DITERPENOID
STEVIOL GLYCOSIDES
Related Applications
This Application claims priority to U.S. Provisional Application No. 61/418,357, filed on November 30, 2010, which is hereby incorporated by reference in its entirety. This Application also claims the benefit of U.S. Application No. 13/249,388, filed September 30, 2011, which is hereby incorporated by reference in its entirety.
Field of the Invention
The invention relates to the production of one or more terpenoids, including steviol and steviol glycosides, through genetic engineering.
Government Interest
This work was funded in part by the National Institutes of Health under Grant Number 1- R01-GM085323-01A1. The government has certain rights in this invention.
Background of the Invention
Steviol glycosides are natural constituents of the plant Stevia rebaudiana Bertoni, referred to as Stevia. Stevia is native to the Amambay region of Northeastern Paraguay and has been reported to grow in neighboring parts of Brazil and Argentina. Although Stevia continues to be a rare plant in its native habitat, it is now farmed in South America and Asia. Stevia leaves have been used to sweeten beverages and make tea. In addition, the leaves are also used for their medicinal benefits in high blood pressure, obesity, topical dressing of wounds and other skin disorders (1).
The crushed Stevia leaves are about 30 times sweeter than sugar (2). The sweet tasting components of the Stevia plant are called steviol glycosides. Steviol glycosides are obtained from the leaves of Stevia rebaudiana Bertoni. The leaves are processed with hot water and aqueous extraction to concentrate and purify the steviol glycosides. The final product may be spray dried. Steviol glycosides preparations are available as white or slightly yellowish white crystalline odorless soluble powders. Summary of the Invention
The current production of steviol glycoside sweeteners solely relies on cultivation of the plant Stevia and extraction of steviol glycosides from the plant, which yields variable mixtures with undesirable taste profiles, and the yield is severely limited by cultivation and extraction procedures. A promising solution to this problem is to engineer fast growing microorganisms such as bacteria and yeast to synthesize steviol glycosides or its precursor molecule steviol that can be chemically converted to steviol glycosides through established inexpensive methods.
Aspects of the present invention relate to methods involving recombinantly expressing a copalyl diphosphate synthase (CPS), kaurene synthase (KS) and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in a cell that expresses (or overexpresses one or more components of) an endogenous isopenoid synthesis pathway, such as the non-mevalonate (MEP) pathway or the mevalonic acid pathway (MVA). In some embodiments the cell is a bacterial cell such as an Escherichia coli cell. In some embodiments, the bacterial cell is a Gram-positive cell such as a Bacillus cell. In some embodiments, the cell is a yeast cell such as a Saccharomyces cell, Pichia cell, or a Yarrowia cell. In some embodiments, the cell is an algal cell or a plant cell.
In some embodiments, the copalyl diphosphate synthase (CPS) enzyme is a Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme. In some embodiments, the kaurene synthase (KS) enzyme is a Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme. In some embodiments, the GGPPS enzyme is a Taxus enzyme such as a Taxus canadenis enzyme or Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme. In some embodiments, the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP pathway is/are expressed from one or more plasmids. In some embodiments, the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP pathway is/are incorporated into the genome of the cell.
In some embodiments, one or more overexpressed components of the non-mevalonate (MEP) pathway are selected from dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB. In certain embodiments, dxs, idi, ispD and ispF are overexpressed in the cell. For example, dxs, idi, ispD and ispF can be expressed or overexpressed on the operon dxs-idi-iSpDF, or ispC, ispE, ispG and ispH can be expressed or overexpressed on the operon ispC-ispE-ispG-ispH. In some embodiments, the gene encoding the copalyl diphosphate synthase (CPS) enzyme, the gene encoding the kaurene synthase (KS) enzyme and the gene encoding the GGPPS enzyme are expressed together on an operon. In some embodiments, the operon is KS-CPS-GGPPS.
In some embodiments, the cell further expresses a kaurene oxidase (KO), a P450 mono- oxygenase, and kaurenoic acid 13-hydroxylase (KAH), a cytochrome P450, or a catalytically active portion thereof. In certain embodiments, the KO and KAH enzyme or a catalytically active portion thereof is fused to a cytochrome P450 reductase enzyme or a catalytically active portion thereof. In some embodiments, the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, and the gene encoding the kaurenoic acid 13-hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, are expressed together on an operon. In some embodiments, the operon is KO-KAH.
In some embodiments, the gene encoding the kaurene oxidase (KO) synthase enzyme, the gene encoding the kaurenoic acid 13-hydroxylase (KAH) enzyme and/or the gene encoding the catalytically active portion thereof fused to a cytochrome P450 reductase enzyme or a catalytically active portion is expressed from one or more plasmids. In some embodiments, the gene encoding the kaurene oxidase (KO) synthase enzyme, the gene encoding the kaurenoic acid 13-hydroxylase (KAH) enzyme and/or the gene encoding the catalytically active portion thereof fused to a cytochrome P450 reductase enzyme or a catalytically active portion is incorporated into the genome of the cell.
In some embodiments, the cell further expresses one or more UDP-glycosyltransferases (UGTs) or a catalytically active portion thereof. In some embodiments, the UDP- glycosyltransferase (UGT) enzyme(s) is a Stevia enzyme such as a Stevia rebaudiana Bertoni enzyme. In some embodiments, the gene encoding for one or more of the UDP- glycosyltransferases (UGTs) or a catalytically active portion are expressed together on an operon. In some embodiments, the gene encoding for the UDP-glycosyltransferases (UGTs) or a catalytically active portion is expressed from one or more plasmids. In some embodiments, the gene encoding for the UDP-glycosyltransferases (UGTs) or a catalytically active portion is incorporated into the genome of the cell.
The expression of the copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS) enzyme, and the one or more components of the MEP pathway can be balanced to maximize production of kaurene. Methods associated with the invention can further encompass culturing a cell to produce kaurene.
The expression of the copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS), kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme, and the one or more components of the MEP pathway, can be balanced to maximize production of steviol. Methods associated with the invention can further encompass culturing a cell to produce steviol.
Methods associated with the invention can further comprise recovering the kaurene, steviol or steviol glycosides from the cell culture. In some embodiments, the kaurene, steviol and/or steviol glycosides is recovered from the gas phase while in other embodiments, an organic layer or polymeric resin is added to the cell culture, and the kaurene, steviol and/or steviol glycosides is recovered from the organic layer or polymeric resin. In some
embodiments, the steviol glycoside is selected from rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, and dulcoside A. In some embodiments, the terpenoid produced is steviobioside or stevioside.
Aspects of the invention relate to cells that express or overexpress an endogenous isoprenoid synthesis pathway, such as MEP or MVA (or are engineered to overexpress one or more components of said pathway), and that recombinantly expresses a copalyl diphosphate synthase (CPS), kaurene synthase (KS), a geranylgeranyl diphosphate synthase (GGPPS) enzyme, kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme. In some embodiments the cell is a bacterial cell such as an Escherichia coli cell, and which overexpresses one or more components of the MEP pathway as described in detail herein. In some embodiments, the bacterial cell is a Gram-positive cell such as a Bacillus cell. In some embodiments, the cell is a yeast cell such as a Saccharomyces cell, Pichia pastoris, or a
Yarrowia cell. In some embodiments, the cell is an algal cell or a plant cell.
Aspects of the invention relate to methods for selecting a cell that exhibits enhanced production of kaurene, steviol or steviol glycosides, including creating or obtaining a cell that expresses or overexpresses one or more components of the mevalonic acid pathway (MVA) or non-mevalonate (MEP) pathway, producing kaurene, steviol or steviol glycosides from the cell, comparing the amount of kaurene, steviol or steviol glycosides produced from the cell to the amount of kaurene, steviol or steviol glycosides produced in a control cell, and selecting a first improved cell that produces a higher amount of kaurene, steviol or steviol glycosides than a control cell, wherein a first improved cell that produces a higher amount of kaurene, steviol or steviol glycosides than the control cell is a cell that exhibits enhanced production of kaurene, steviol or steviol glycosides. In some embodiments, the steviol or steviol glycoside is steviobioside, stevioside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, or dulcoside A.
In some embodiments, the cell recombinantly expresses a copalyl diphosphate synthase (CPS) enzyme and/or a kaurene synthase (KS) enzyme and/or a geranylgeranyl diphosphate synthase (GGPPS) enzyme. Methods can further comprise altering the level of expression of one or more of the components of the non-mevalonate (MEP) pathway, the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme and/or the geranylgeranyl diphosphate synthase (GGPPS) enzyme in the first improved cell to produce a second improved cell, and comparing the amount of kaurene produced from the second improved cell to the amount of kaurene produced in the first improved cell, wherein a second improved cell that produces a higher amount of kaurene than the first improved cell is a cell that exhibits enhanced production of kaurene. In some embodiments, the copalyl diphosphate synthase (CPS) and/or the kaurene synthase (KS) enzyme is a Stevia enzyme, optionally a Stevia rebaudiana Bertoni enzyme. The cell can further recombinantly express any of the polypeptides associated with the invention.
Aspects of the invention relate to isolated polypeptides comprising a kaurene oxidase (KO) enzyme, kaurenoic acid 13 -hydroxylase (KAH) enzyme or a catalytically active portion of KO or KAH fused to a cytochrome P450 reductase enzyme or a catalytically active portion thereof. In some embodiments, the cytochrome P450 reductase enzyme is a Taxus cytochrome P450 reductase (TCPR). In certain embodiments, the kaurene oxidase (KO) enzyme or kaurenoic acid 13 -hydroxylase (KAH) enzyme and TCPR are joined by a linker such as GSTGS (SEQ ID NO: 15). In some embodiments, the kaurene oxidase (KO) enzyme, kaurenoic acid 13- hydroxylase (KAH) enzyme or TCPR are truncated to remove all or part of the transmembrane region. In some embodiments, an additional peptide is fused to kaurene oxidase (KO) enzyme and/or kaurenoic acid 13 -hydroxylase (KAH). In certain embodiments, the additional peptide is from bovine 17a hydroxylase. In certain embodiments, the peptide is MALLLAVF (SEQ ID NO: 16). Aspects of the invention also encompass nucleic acid molecules that encode any of the polypeptides associated with the invention and cells that recombinantly express any of the polypeptides associated with the invention.
Aspects of the invention relate to methods for increasing terpenoid production in a cell that produces one or more terpenoids, such as kaurene, steviol or steviol glycosides. The methods include controlling the accumulation of indole in the cell or in a culture of the cells, thereby increasing terpenoid production in a cell. Any of the cells described herein can be used in the methods, including bacterial cells, such as Escherichia coli cells; Gram-positive cells, such as Bacillus cells; yeast cells, such as Saccharomyces cells, Pichia cells, or Yarrowia cells; algal cells; plant cells; and any of the engineered cells described herein.
In some embodiments, the step of controlling the accumulation of indole in the cell or in a culture of the cells includes balancing the upstream non-mevalonate isoprenoid pathway with the downstream product synthesis pathways and/or modifying or regulating the indole pathway. In other embodiments, the step of controlling the accumulation of indole in the cell or in a culture of the cells includes or further includes removing the accumulated indole from the fermentation through chemical methods, such as by using absorbents or scavengers.
Aspects of the invention relate to methods that include measuring the amount or concentration of indole in a cell that produces one or more terpenoids, such as kaurene, steviol or steviol glycosides, or in a culture of the cells that produce one or more terpenoids, such as kaurene, steviol or steviol glycosides. The methods can include measuring the amount or concentration of indole two or more times. In some embodiments, the measured amount or concentration of indole in the cell or cells is used to guide a process of producing one or more terpenoids. In some embodiments, the measured amount or concentration of indole is used to guide strain construction.
In other aspects, the invention provides a method for making a product containing a terpenoid selected from kaurene, a steviol, or a steviol glycoside. The method comprises increasing terpenoid production in a cell that produces one or more terpenoids by controlling the accumulation of indole in the cell or in a culture of the cells. The terpenoid is recovered from the cell(s), and optionally, one or more chemical or enzymatic steps may be performed to produce the desired compound. The recovered terpenoid or the terpenoid prepared through one or more chemical or enzymatic steps, is incorporated into a product to thereby make the product containing a terpenoid. In various embodiments, the product is a food product or beverage. These and other aspects of the invention, as well as various embodiments thereof, will become more apparent in reference to the drawings and detailed description of the invention.
Brief Description of the Drawings
The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:
Figure 1. Biosynthetic scheme for steviol glycoside production. Schematics of the four modules, the native, upstream isoprenoid pathway (steps I to VII), synthetic downstream kaurene (steps VIII to X), steviol (steps XI and XII), and steviol glycoside (bottom panel). In the biosynthetic network, divergence of the MEP isoprenoid pathway from glycolysis initiates at the precursors glyceraldehyde-3 phosphate (G3P) and pyruvate (PYR) (I- VII). The steviol pathway bifurcation starts from the E. coli isoprenoid precursor IPP and DMAPP to the "linear" precursor geranylgeranyl diphosphate (VIII), copalyl diphosphate (CP) (IX), "cyclic" karuene (X), "oxidized" kaurenoic acid (XI), and steviol (XII), followed by multiple rounds of glycosylations to steviol glycosides. The enzymes involved in the biosynthetic pathways from G3P and PYR to steviol glycosides include: DXS-l-deoxy-D-xylulose-5-phosphate synthase, ispC-l-Deoxy-D-xylulose-5-phosphate reductoisomerase, IspD-4-diphosphocytidyl-2C-methyl- D-erythritol synthase, IspE-4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, IspF-2C- Methyl-D-erythritol-2,4-cyclodiphosphate Synthase, IspG- l-hydroxy-2-methyl-2-(E)-butenyl-4- diphosphate synthase, IspH-4-hydroxy-3-methyl-2-(E)-butenyl-4-diphosphate reductase, IDI- isopentenyl-diphosphate isomerase, GGPPS-geranyl geranyldiphosphate synthase, CPS-copalyl diphosphate synthase, KS-kaurene synthase, KO-kaurene oxidase, KAH-kaurenoic acid 13- hydroxylase, and UGT-UDP-glycosyltransferases.
Figure 2. Schematics of the chemical synthesis of steviol glycosides to rebaudioside A. Specifically a trimethylsilyl (TMS) protected at C19 COOH group of the steviol is synthesized from the microbially derived steviol. Further, tri-glucosylation at C13 -OH position of the steviol is performed using protected -Glc- -Glc(2→l)- -Glc(3→l) group. This is followed by a deprotection of the TMS and coupling of protected mono β-Glc-Br moiety. The final deprotection will remove all of the protecting groups to produce rebaudioside A.
Figure 3. Multivariate-modular engineering of steviol glycosides. (A) Modularization of rebaudioside D (Reb D) biosynthetic pathway. (B) Schematics of the modular pathway and the production of committed cyclic diterpenoid precursor kaurene from the engineered E. coli strains. Experimentation with four strains on a small upstream and downstream expression profile showed significant differences in kaurene production between strains, with one E. coli strain showing production of 45 mg/L.
Figure 4. Correlation between indole accumulation and kaurene production. The GC chromato graph of the two strains show low (ChlT7MEP-p20TrcKCG) and high (ChlTrcMEP-p5T7KCG) accumulation of kaurene. The peak 1 and 2 corresponds to indole and kaurene respectively. The corresponding MS spectra are shown in the right.
Detailed Description of the Invention
Steviol glycosides are of recent immense interest to the food and beverages industry due to their intense sweetening properties and as a potential alternative to synthetic sweeteners. Stevia leaves accumulate a mixture of at least eight steviol glycosides. Here, we describe a multivariate-modular approach to metabolic pathway engineering for the production of steviol or steviol in engineered cells including bacterial cells such as Escherichia coli and yeast such as Saccharomyces cerevisiae.
Unless recited in a claim, this invention as claimed is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
The worldwide demand for high potency sweeteners is increasing, and with blending of different sweeteners becoming a standard practice, the demand and supply for alternatives such as pure steviol glycoside is expected to increase. Developing technology for the production of high purity steviol glycosides such as Rebaudioside A (Reb A) would have significant changes on the political and socio economics of current non-caloric sweetener use in food and beverages (F&B) industry (3). Recently, Coca-Cola company released the details of the production of high purity Reb A from plant extracted steviol glycoside mixture following food grade specifications and GMP manufacturing for human consumption (4). Clinical, biochemical and metabolic studies support Reb A as general purpose-sweetener for human consumption (5). This is reflected in the recent FDA approval for Reb A as GRAS for use as general purpose sweetener in food and beverages industry. The featured markets and uses for this molecule are (i) soft drinks and cordials; (ii) milk, soy and mineral drinks; (iii) canned fruit, jams and juices; (iv) ice creams, yoghurts, and other dietary products; (v) cakes, biscuits, pastries and desserts; (vi) sugar free beers and alcoholic beverages; (vii) toppings, sauces, chutneys, spreads, etc. and; (viii) cereals, muesli bars and confectionaries (3). Thus Reb A is a high value chemical in the multibillion dollar F&B industry. Developing a sustainable and economical production process for Reb A not only has commercial interest but also potential health implications, due to the extensive history of use as a natural herbal sweetener and medicine.
Stevia leaves accumulate a mixture of at least eight steviol glycosides. The details of major steviol glycosides characterized from the Stevia are shown in Table 1. The diversity of various steviol glycosides results from the differences in the glycosylation on the diterpenoid skeleton, steviol, which primarily determines the sweetening property of these molecules.
Stevioside is the main sweetening compound found in the Stevia leaf (2- 10%), followed by Reb A (-1-3%) (1). Stevioside and Reb A were tested for stability in carbonated beverages and found to be both heat and pH stable.
Table 1. Details of steviol glycosides characterized from Stevia rebaudiana Bertoni leaf
Figure imgf000012_0001
The sweetening properties of Stevia extract are derived from stevioside and Reb A molecules. Stevioside is reported to be 143 times sweeter than sucrose on a weight basis and Reb A is 242 times sweeter (1). However the taste quality of Reb A is better than stevioside, because it is sweeter and less bitter. Thus in the natural extract the taste "quality" is determined by the percentage composition of stevioside and Reb A. If stevioside is more than 50%, the taste is "common/traditional" with a "licorice" aftertaste, whereas if Reb A is more than 50%, the taste is improved with a reduced aftertaste (2). Thus developing high Reb A steviol glycosides is important for its use as sweeteners. However, the extraction and purification from plant leaf is technically challenging due to (i) low accumulation (2-10 wt%), (ii) production of steviol glycosides depends on the cultivation method and climate, and (iii) the difficulty in extracting Reb A from a mixture of structurally similar steviol glycosides.
Recent developments in metabolic engineering and synthetic biology offer new possibilities for the overproduction of complex natural products such as steviol glycosides through more technically amenable microbial hosts (6, 7). Steviol glycosides are diterpenoids and the early biosynthetic pathway until GGPP share common intermediates with other diterpenoid such as Taxol biosynthetic pathway (8). Similar to Taxol biosynthesis, the overall pathway is modularized into parts: 1) the formation of starting precursor IPP and DMAPP from the central carbon metabolites glyceraldehydes-3-phosphate and pyruvate (Figure 1, blue structures); 2) the production of the first dedicated intermediate, kaurene (Figure 1, red structures); 3) biosynthesis of the key intermediate, steviol (Figure 1, gray structures); and 4) the formation various steviol glycosides (Figure 1, black structures).
In plants, the formation of common isoprenoid precursor IPP and DMAPP can be derived from two biosynthetic routes, the MVA and MEP pathway. The first step in the diterpenoid steviol biosynthesis is conversion of IPP and DMAPP into GGPP. GGPP is the four subunit precursor for all diterpenoid molecules. Next, the cyclization of the GGPP, first by protonation-initiated cyclization to copalyl diphosphate (CDP) is catalyzed by CDP synthase (CPS). Kaurene is then produced from CDP by an ionization dependant cyclization catalysed by kaurene synthase (KS). These enzymes have been identified and characterized from the native biosynthetic pathway in Stevia (8).
Kaurene is then oxidized in a three step reaction to kaurenoic acid, by kaurene oxidase (KO) a P450 mono-oxygenase. A full length KO cDNA was expressed in yeast and
demonstrated that it could convert kaurene to kaurenoic acid. The next step in the pathway is the hydroxylation of kaurenoic acid by kaurenoic acid 13 -hydroxylase (KAH). KAH, a cytochrome P450, was expressed in yeast and converted kaurenoic acid to steviol(9).
Aglycone steviol has two hydroxyl groups, one attached to the C- 19 of the C-4 carboxyl and the other attached to the C-13, both of which in theory can be glycosylated using UDP- glycosyltransferases (UGTs) (10). In vitro enzyme studies using 13-0- and 19-O-methylsteviol as substrates found that only 19-O-steviol could serve as a substrate and concluded that synthesis of steviol glycosides starts with the glucosylation of the 13-hydroxyl of steviol, which produces steviolmonoside. The next step is the glucosylation of the C-20 of the 13-O-glucose of steviolmonoside, which results in the production of steviolbioside. Stevioside is then produced by the glycosylation of the C-19 carboxyl of steviolbioside. In vitro studies on various substrates shows that C-19 is glucosylated after the glucosylation of the C2' of the C13-glucose of steviolmonoside.
Reb A is then synthesized by glucosylation of the C-3' of the C-13-O-glucose. Further, no product was observed using Reb A as a substrate, indicating it is the terminal step in the pathway. The tri-glycoside stevioside and the tetra-glycoside Reb A typically represent the majority of the steviol glycosides present in Stevia leaves. In addition to these, rhamnosylated glycosides can also be formed by addition of a UDP rhamnose moiety to steviolmonoside, and in genotypes enriched in Reb A C, the C2' of the C13-glucose can be xylosylated to form rebaudioside F.
The detailed understanding and characterization of biochemical pathways for steviol glycosides and the recent advancements in engineering of the upstream isoprenoid pathway to reroute the IPP and DMAPP through heterologous biosynthetic pathway engineering provides the basis for directed, heterologous production of steviol glycosides in a convenient microbial- based bioprocess. There are nine steps in the pathway for the biosynthesis of Reb A of which one glycosylation remains unidentified.
As mentioned above, the current Sievia-based production and purification present significant challenges to reduce production costs. Our proposed synthetic route using heterologous pathways that have been reconstructed through amenable microbial hosts offers superior opportunities for improving current production schemes and to generate new derivatives of steviosides which are not naturally occurring. In addition, the microbial systems lend themselves to metabolic engineering efforts through a combination of genetic
manipulations and bioprocess engineering to continually improve production capabilities.
Taken together, the above provide several compelling reasons to reconstitute the Reb A biosynthesis through simpler microbial hosts.
The metabolic pathway for steviol glycosides consists of an upstream isoprenoid pathway that is native to E. coli and a heterologous downstream terpenoid pathway (Fig. 1). The upstream mevalonic acid (MVA) pathway in certain microbial organisms such as yeast or methylerythritol phosphate (MEP) pathway in certain microbial organisms such as E. coli can produce the two common building blocks, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), from which isoprenoid compounds are formed (7). Microbial production of terpenoids such as kaurene and steviol is demonstrated herein. When expressed at satisfactory levels, microbial routes reduce dramatically the cost of production of such compounds. Additionally, they utilize cheap, abundant and renewable feedstocks (such as sugars and other carbohydrates) and can be the source for the synthesis of numerous derivatives that may exhibit far superior properties than the original compound. A key element in the cost-competitive production of compounds of the isoprenoid pathway using a microbial route is the amplification of this pathway in order to allow the overproduction of these molecules.
Described herein are methods and compositions for optimizing production of terpenoids in cells by controlling expression of genes or proteins participating in an upstream pathway and a downstream pathway. The upstream pathway involves production of isopentyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which can be achieved by two different metabolic pathways: the mevalonic acid (MVA) pathway and the MEP (2-C-methyl-D-erythritol 4-phosphate) pathway, also called the MEP/DOXP (2-C-methyl-D-erythritol 4-phosphate/l- deoxy-D-xylulose 5-phosphate) pathway, the non-mevalonate pathway or the mevalonic acid- independent pathway.
The downstream pathway is a synthetic pathway that leads to production of a terpenoids and involves recombinant gene expression of a terpenoid synthase (also referred to as terpene cyclase) enzyme, and a geranylgeranyl diphosphate synthase (GGPPS) enzyme. In some embodiments, a terpenoid synthase enzyme is a diterpenoid synthase enzyme. Several non- limiting examples of diterpenoid synthase enzymes include copalyl diphosphate synthase (CPS) and kaurene synthase (KS).
The optimization of terpenoid synthesis by manipulation of the upstream and
downstream pathways described herein is not a simple linear or additive process. Rather, through complex combinatorial analysis, optimization is achieved through balancing
components of the upstream and downstream pathways.
Aspects of the invention relate to controlling the expression of genes and proteins in the MEP pathway for optimized production of a terpenoid. Optimized production of a terpenoid refers to producing a higher amount of a terpenoid following pursuit of an optimization strategy than would be achieved in the absence of such a strategy. It should be appreciated that any gene and/or protein within the MEP pathway is encompassed by methods and compositions described herein. In some embodiments, a gene within the MEP pathway is one of the following: dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA or ispB. Expression of one or more genes and/or proteins within the MEP pathway can be upregulated and/or downregulated. In certain embodiments, upregulation of one or more genes and/or proteins within the MEP pathway can be combined with downregulation of one or more genes and/or proteins within the MEP pathway.
It should be appreciated that genes and/or proteins can be regulated alone or in combination. For example, the expression of dxs can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB. The expression of ispC can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB. The expression of ispD can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispE, ispF, ispG, ispH, idi, ispA and ispB. The expression of ispE can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispF, ispG, ispH, idi, ispA and ispB. The expression of ispF can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispG, ispH, idi, ispA and ispB. The expression of ispG can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispH, idi, ispA and ispB. The expression of ispH can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, idi, ispA and ispB. The expression of idi can be upregulated or downregulated alone or in combination with
upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, ispA and ispB. The expression of ispA can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi and ispB. The expression of ispB can be upregulated or downregulated alone or in combination with upregulation or downregulation of expression of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi and ispA. In some embodiments, expression of the gene and/or protein of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, and idi is upregulated while expression of the gene and/or protein of ispA and/or ispB is downregulated. Expression of genes within the MEP pathway can be regulated in a modular method. As used herein, regulation by a modular method refers to regulation of multiple genes together. For example, in some embodiments, multiple genes within the MEP pathway are recombinantly expressed on a contiguous region of DNA, such as an operon. It should be appreciated that a cell that expresses such a module can also express one or more other genes within the MEP pathway either recombinantly or endogenously.
A non-limiting example of a module of genes within the MEP pathway is a module containing the genes dxs, idi, ispD and ispF, referred to herein as dxs-idi-ispDF. It should be appreciated that modules of genes within the MEP pathway, consistent with aspects of the invention, can contain any of the genes within the MEP pathway, in any order.
Expression of genes and proteins within the downstream synthetic terpenoid synthesis pathway can also be regulated in order to optimize terpenoid production. The synthetic downstream terpenoid synthesis pathway involves recombinant expression of a terpenoid synthase enzyme and a GGPPS enzyme. Any terpenoid synthase enzyme, as discussed above, can be expressed with GGPPS depending on the downstream product to be produced. For example, CPS and KS is used for the production of kaurene. Recombinant expression of the CPS and KS enzyme and the GGPPS enzyme can be regulated independently or together. In some embodiments the three enzymes are regulated together in a modular fashion. For example the three enzymes can be expressed in an operon in any order (e.g., GGPPS-CPS-KS, referred to as "GCK," or KS-CPS-GGPPS, referred to as "KCG" or KS-GGPPS-CPS, referred to as "KGC" or GGPPS-KS-CPS, referred to as "GKC").
The synthetic downstream steviol synthesis pathway also involves recombinant expression of P450 mono-oxygenases such as kaurene oxidase (KO) and kaurenoic acid 13- hydroxylase (KAH) enzyme. Any P450 mono-oxygenases, as discussed above, can be expressed with CPS and KS synthase enzyme and the GGPPS enzyme on the downstream product to be produced. For example, kaurene oxidase (KO) and kaurenoic acid 13 -hydroxylase (KAH) enzyme are used for the production of steviol from kaurene. Recombinant expression of the kaurene oxidase (KO) and kaurenoic acid 13 -hydroxylase (KAH) enzyme and/or a gene encoding for a catalytically active portion thereof is fused to a cytochrome P450 reductase enzyme (CPR) (to form KOCPR and KAHCPR fusions) or a catalytically active portion can be regulated independently or together. In some embodiments these two enzymes are regulated together in a modular fashion. For example the two enzymes can be expressed in an operon in either order (KOCPR-KAHCPR, or KAHCPR-KOCPR).
Manipulation of the expression of genes and/or proteins, including modules such as the dxs-idi-ispDF operon, the GGPPS-CPS-KS operon, and the KOCPR-KAHCPR operon, can be achieved through various methods. For example, expression of the genes or operons can be regulated through selection of promoters, such as inducible promoters, with different strengths. Several non-limiting examples of promoters include Trc, T5 and T7. Additionally, expression of genes or operons can be regulated through manipulation of the copy number of the gene or operon in the cell. For example, in certain embodiments, a strain containing an additional copy of the dxs-idi-ispDF operon on its chromosome under Trc promoter control produces an increased amount of taxadiene relative to one overexpressing only the synthetic downstream pathway. In some embodiments, expression of genes or operons can be regulated through manipulating the order of the genes within a module. For example, in certain embodiments, changing the order of the genes in a downstream synthetic operon from GCK to KCG or KGC or GKC and KOCPR-KAHCPR to KAHCPR-KOCPR results in an increase in steviol production. In some embodiments, expression of genes or operons is regulated through integration of one or more genes or operons into a chromosome. For example, in certain embodiments, integration of the upstream dxs-idi-ispDF operon into the chromosome of a cell results in increased
production.
In some embodiments, the dxs-idi-ispD-ispF operon and the K-C-G operon are controlled by the same promoter, such as the T7 promoter, or promoters of similar strength.
It should be appreciated that the genes associated with the invention can be obtained from a variety of sources. In some embodiments, the genes within the MEP pathway are bacterial genes such as Escherichia coli genes. In some embodiments, the gene encoding for GGPPS is a plant gene. For example, the gene encoding for GGPPS can be from a species of Taxus such as Taxus canadensis (T. canadensis) or Stevia such as Stevia rebaudiana Bertoni. In some embodiments, the gene encoding for CPS and/or KS synthase is a plant gene. For example, the gene encoding for CPS and KS synthase can be from a species of Stevia such as Stevia rebaudiana Bertoni. Representative GenBank Accession numbers for T. canadensis GGPPS, Stevia rebaudiana GGPPS, CPS and KS are provided by AF081514, ABD92926, AAB87091, and AF097311_1 respectively, the sequences of which are incorporated by reference herein in their entireties. Exemplary protein sequences for a number of the enzymes described herein are provided in Table 2.
As one of ordinary skill in the art would be aware, homologous genes for use in methods associated with the invention can be obtained from other species and can be identified by homology searches, for example through a protein BLAST search, available at the National Center for Biotechnology Information (NCBI) internet site (www.ncbi.nlm.nih.gov). Genes and/or operons associated with the invention can be cloned, for example by PCR amplification and/or restriction digestion, from DNA from any source of DNA which contains the given gene. In some embodiments, a gene and/or operon associated with the invention is synthetic. Any means of obtaining a gene and/or operon associated with the invention is compatible with the instant invention.
In some embodiments, further optimization of terpenoid production is achieved by modifying a gene before it is recombinantly expressed in a cell. In some embodiments, the GGPPS enzyme has one or more of the follow mutations: A162V, G140C, L182M, F218Y, D160G, C184S, K367R, A151T, M185I, D264Y, E368D, C184R, L331I, G262V, R365S, A114D, S239C, G295D, I276V, K343N, P183S, I172T, D267G, I149V, T234I, E153D and T259A (wherein the numbering refers to amino acids of T. canadensis GGPPS [see GenBank accession numbers AF081514 and AAD16018]; residues at equivalent positions of other GGPPS enzymes can likewise be mutated). In some embodiments, the GGPPS enzyme has a mutation in residue S239 and/or residue G295. In certain embodiments, the GGPPS enzyme has the mutation S239C and/or G295D.
In some embodiments, modification of a gene before it is recombinantly expressed in a cell involves codon optimization for expression in a bacterial cell. Codon usages for a variety of organisms can be accessed in the Codon Usage Database (www.kazusa.or.jp/codon/). Codon optimization, including identification of optimal codons for a variety of organisms, and methods for achieving codon optimization, are familiar to one of ordinary skill in the art, and can be achieved using standard methods.
In some embodiments, modifying a gene before it is recombinantly expressed in a cell involves making one or more mutations in the gene before it is recombinantly expressed in a cell. For example, a mutation can involve a substitution or deletion of a single nucleotide or multiple nucleotides. In some embodiments, a mutation of one or more nucleotides in a gene will result in a mutation in the protein produced from the gene, such as a substitution or deletion of one or more amino acids. Such modifications are made using standard molecular biology methods well known in the art.
In some embodiments, it may be advantageous to use a cell that has been optimized for production of a terpenoid. For example, in some embodiments, a cell that overexpresses one or more components of the non-mevalonate (MEP) pathway is used, at least in part, to amplify isopentyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), substrates of GGPPS. In some embodiments, overexpression of one or more components of the non-mevalonate (MEP) pathway is achieved by increasing the copy number of one or more components of the non- mevalonate (MEP) pathway. For example, copy numbers of components at rate-limiting steps in the MEP pathway such as (dxs, ispD, ispF, idi) can be amplified, such as by additional episomal expression.
In some embodiments "rational design" is involved in constructing specific mutations in proteins such as enzymes. As used herein, "rational design" refers to incorporating knowledge of the enzyme, or related enzymes, such as its three dimensional structure, its active site(s), its substrate(s) and/or the interaction between the enzyme and substrate, into the design of the specific mutation. Based on a rational design approach, mutations can be created in an enzyme which can then be screened for increased production of a terpenoid relative to control levels. In some embodiments, mutations can be rationally designed based on homology modeling. As used herein, "homology modeling" refers to the process of constructing an atomic resolution model of one protein from its amino acid sequence and a three-dimensional structure of a related homologous protein.
In some embodiments, random mutations can be made in a gene, such as a gene encoding for an enzyme, and these mutations can be screened for increased production of a product, such as a terpenoid and/or steviol glycoside, relative to control levels. For example, screening for mutations in components of the MEP pathway, or components of other pathways, that lead to enhanced production of a product, such as a terpenoid and/or steviol glycoside, may be conducted through a random mutagenesis screen, or through screening of known mutations. In some embodiments, shotgun cloning of genomic fragments could be used to identify genomic regions that lead to an increase in production of a product, such as a terpenoid and/or steviol glycoside, through screening cells or organisms that have these fragments for increased production of a terpenoid. In some cases one or more mutations may be combined in the same cell or organism. In some embodiments, production of a product, such as a terpenoid and/or steviol glycoside in a cell can be increased through manipulation of enzymes that act in the same pathway as the enzymes associated with the invention. For example, in some embodiments it may be advantageous to increase expression of an enzyme or other factor that acts upstream of a target enzyme such as an enzyme associated with the invention. This could be achieved by over- expressing the upstream factor using any of the standard methods known in the art.
Optimization of protein expression can also be achieved through selection of appropriate promoters and ribosome binding sites. In some embodiments, this may include the selection of high-copy number plasmids, or low or medium-copy number plasmids. The step of transcription termination can also be targeted for regulation of gene expression, through the introduction or elimination of structures such as stem-loops.
Aspects of the invention relate to expression of recombinant genes in cells. The invention encompasses any type of cell that recombinantly expresses genes associated with the invention, including prokaryotic and eukaryotic cells. In some embodiments the cell is a bacterial cell, such as Escherichia spp., Streptomyces spp., Zymonas spp., Acetobacter spp., Citrobacter spp., Synechocystis spp., Rhizobium spp., Clostridium spp., Corynebacterium spp., Streptococcus spp., Xanthomonas spp., Lactobacillus spp., Lactococcus spp., Bacillus spp., Alcaligenes spp., Pseudomonas spp., Aeromonas spp., Azotobacter spp., Comamonas spp., Mycobacterium spp., Rhodococcus spp., Gluconobacter spp., Ralstonia spp., Acidithiobacillus spp., Microlunatus spp., Geobacter spp., Geobacillus spp., Arthrobacter spp., Flavobacterium spp., Serratia spp., Saccharopolyspora spp., Thermus spp., Stenotrophomonas spp.,
Chromobacterium spp., Sinorhizobium spp., Saccharopolyspora spp., Agrobacterium spp. and Pantoea spp. The bacterial cell can be a Gram- negative cell such as an Escherichia coli (E. coli) cell, or a Gram-positive cell such as a species of Bacillus. In other embodiments, the cell is a fungal cell such as a yeast cell, e.g., Saccharomyces spp., Schizosaccharomyces spp., Pichia spp., Paffia spp., Kluyveromyces spp., Candida spp., Talaromyces spp., Brettanomyces spp., Pachysolen spp., Debaryomyces spp., Yarrowia spp., and industrial polyploid yeast strains. Preferably the yeast strain is a S. cerevisiae strain or a Yarrowia spp. strain. Other examples of fungi include Aspergillus spp., Pennicilium spp., Fusarium spp., Rhizopus spp., Acremonium spp., Neurospora spp., Sordaria spp., Magnaporthe spp., Allomyces spp., Ustilago spp., Botrytis spp., and Trichoderma spp. In other embodiments, the cell is an algal cell, or a plant cell. It should be appreciated that some cells compatible with the invention may express an endogenous copy of one or more of the genes associated with the MEP and/or MVA pathways as well as a recombinant copy. In some embodiments, if a cell has an endogenous copy of one or more of the genes associated with the MEP or MVA pathway then the methods will not necessarily require adding a recombinant copy of the gene(s) that are endogenously expressed. In some embodiments the cell may endogenously express one or more enzymes from the pathways described herein and may recombinantly express one or more other enzymes from the pathways described herein for efficient production of a product, such as a terpenoid and/or steviol glycoside.
Further aspects of the invention relate to screening for bacterial cells or strains that exhibit optimized production of a product, such as a terpenoid and/or steviol glycoside. As described above, methods associated with the invention involve generating cells that
overexpress one or more genes in the MEP pathway. Terpenoid production from culturing of such cells can be measured and compared to a control cell wherein a cell that exhibits a higher amount of production of product, such as a terpenoid and/or steviol glycoside, relative to a control cell is selected as a first improved cell. The cell can be further modified by recombinant expression of a terpenoid synthase enzyme and a GGPPS enzyme. The level of expression of one or more of the components of the non-mevalonate (MEP) pathway, the terpenoid synthase enzyme and/or the GGPPS enzyme in the cell can then be manipulated and terpenoid and/or steviol glycoside production can be measured again, leading to selection of a second improved cell that produces greater amounts of product, such as a terpenoid and/or steviol glycoside, than the first improved cell. In some embodiments, the terpenoid synthase enzyme is a CPS and/or KS enzymes.
Further aspects of the invention relate to the level of accumulation of the metabolite, indole, can be controlled by genetically manipulating the microbial pathway by the
overexpression, down regulation or mutation of the isoprenoid pathway genes. The metabolite indole anti-correlates as a direct variable to the diterpenoid production in engineered strains. Further controlling the accumulation of indole for improving the flux towards terpenoid biosynthesis in bacterial systems (specifically in cells, such as E. coli cells) or other cells, can be achieved by balancing the upstream non-mevalonate isoprenoid pathway with the downstream product synthesis pathways or by modifications to or regulation of the indole pathway. In so doing, the skilled person can reduce or control the accumulation of indole and thereby reduce the inhibitory effect of indole on the production of steviol and steviol glycosides. Other methods for reducing or controlling the accumulation of indole include removing the accumulated indole from the fermentation through chemical methods such as by using absorbents, scavengers, etc.
In other embodiments, methods are provided that include measuring the amount or concentration of indole in a cell that produces one or more terpenoids or in a culture of the cells that produce one or more terpenoids. The amount or concentration of indole can be measured once, or two or more times, as suitable, using methods known in the art and as described herein. Such methods can be used to guide processes of producing one or more terpenoids, e.g., in process improvement. Such methods can be used to guide strain construction, e.g., for strain improvement.
As demonstrated previously, by genetically engineering the non-mevalonate isoprenoid pathway in E. coli the accumulation of this metabolite can now be controlled which regulates the flux towards the isoprenoid biosynthesis in bacterial E. coli cells.
Further aspects of the invention relate to chimeric P450 enzymes. Functional expression of plant cytochrome P450 has been considered challenging due to the inherent limitations of bacterial platforms, such as the absence of electron transfer machinery, cytochrome P450 reductases, and translational incompatibility of the membrane signal modules of P450 enzymes due to the lack of an endoplasmic reticulum.
In some embodiments, the KO and KAH associated with methods of the invention is optimized through N-terminal transmembrane engineering and/or the generation of chimeric enzymes through translational fusion with a CPR redox partner. In some embodiments, the CPR redox partner is a Stevia cytochrome P450 reductase. In certain embodiments, the gene encoding for KO and KAH synthase can be from a species of Stevia such as Stevia rebaudiana Bertoni. Representative GenBank Accession numbers for Stevia rebaudiana KO and KAH are provided by ABA42921 and ACD93722, the sequence of which is incorporated by reference herein). In some embodiments, Stevia NADPH: cytochrome P450 reductase (SCPR) is obtained from Stevia rebaudiana Bertoni (GenBank Accession number ABB88839, the sequence of which is incorporated by reference herein).
The KO, KAH and TCPR (or SCPR) can be joined by a linker such as GSTGS (SEQ ID NO: 15). In some embodiments, KO, KAH, TCPR and/or SCPR are truncated to remove all or part of the transmembrane region of one or both proteins. An additional peptide can also be fused to KO and KAH. For example, one or more amino acids from bovine 17a hydroxylase can be added to KO and KAH. In certain embodiments, the peptide MALLLAVF (SEQ ID NO: 16) is added to KO and KAH. In certain embodiments, a chimeric enzyme constructed from the KO and SCPR is capable of carrying out the first oxidation step kaurene conversion to kaurenoic acid. In certain embodiments, a chimeric enzyme constructed from KAH and SCPR is capable of carrying out the hydroxylation step kaurenoic acid to steviol.
Further aspects of the invention relate to glycosylation of steviol on the C-4 carboxyl and to the C-13 using UDP-glycosyltransferases (UGTs). In some embodiments, the UGTs associated with methods of the invention are optimized through N-terminal transmembrane engineering and/or the generation of chimeric enzymes through domain swapping with other plant UGTs. In certain embodiments, the gene encoding for plant UGTs for the synthesis of steviol glycosides can be from a species of Stevia such as Stevia rebaudiana Bertoni.
Representative GenBank Accession numbers for Stevia rebaudiana UGTS are provided by AAM53963, AAR06921, AAR06920, AAR06917, AAN40684, and ACE87855, the sequences of which is incorporated by reference herein.
In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the first glucosylation step steviol to steviolmonoside. In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the glucosylation of the C-20 of the 13-O-glucose of steviolmonoside, which results in the production of steviolbioside. In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the glucosylation of the glycosylation of the C-19 carboxyl of steviolbioside, which results in the production of Stevioside. In certain embodiments, a chimeric enzyme constructed from the UGTs is capable of carrying out the glucosylation of the C-3' of the C- 13-O-glucose, which results in the production of Rebaudioside A (Reb A).
In some embodiments, at least one enzymatic step, such as one or more glycosylation steps, are performed ex vivo.
As used herein, the terms "protein" and "polypeptide" are used interchangeably and thus the term polypeptide may be used to refer to a full-length polypeptide and may also be used to refer to a fragment of a full-length polypeptide. As used herein with respect to polypeptides, proteins, or fragments thereof, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in production, nature, or in vivo systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be obtained naturally or produced using methods described herein and may be purified with techniques well known in the art. Because an isolated protein may be admixed with other components in a preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e.
isolated from other proteins.
The invention also encompasses nucleic acids that encode for any of the polypeptides described herein, libraries that contain any of the nucleic acids and/or polypeptides described herein, and compositions that contain any of the nucleic acids and/or polypeptides described herein.
In some embodiments, one or more of the genes associated with the invention is expressed in a recombinant expression vector. As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence or sequences may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA, although RNA vectors are also available. Vectors include, but are not limited to: plasmids, fosmids, phagemids, virus genomes and artificial chromosomes.
A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host cell such as a host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase.
An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β-galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.
As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame- shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript can be translated into the desired protein or polypeptide.
When the nucleic acid molecule that encodes any of the enzymes of the claimed invention is expressed in a cell, a variety of transcription control sequences (e.g.,
promoter/enhancer sequences) can be used to direct its expression. The promoter can be a native promoter, i.e., the promoter of the gene in its endogenous context, which provides normal regulation of expression of the gene. In some embodiments the promoter can be constitutive, i.e., the promoter is unregulated allowing for continual transcription of its associated gene. A variety of conditional promoters also can be used, such as promoters controlled by the presence or absence of a molecule.
The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. In particular, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.
Expression vectors containing all the necessary elements for expression are
commercially available and known to those skilled in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (14). That heterologous DNA (14) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell. Heterologous expression of genes associated with the invention, for production of a terpenoid, such as taxadiene, is demonstrated in the Examples section using E. coli. The novel method for producing terpenoids can also be expressed in other bacterial cells, fungi (including yeast cells), plant cells, etc.
A nucleic acid molecule that encodes an enzyme associated with the invention can be introduced into a cell or cells using methods and techniques that are standard in the art. For example, nucleic acid molecules can be introduced by standard protocols such as transformation including chemical transformation and electroporation, transduction, particle bombardment, etc. Expressing the nucleic acid molecule encoding the enzymes of the claimed invention also may be accomplished by integrating the nucleic acid molecule into the genome.
In some embodiments one or more genes associated with the invention is expressed recombinantly in a bacterial and yeast cell. Bacterial and yeast cells according to the invention can be cultured in media of any type (rich or minimal) and any composition. As would be understood by one of ordinary skill in the art, routine optimization would allow for use of a variety of types of media. The selected medium can be supplemented with various additional components. Some non-limiting examples of supplemental components include glucose, antibiotics, IPTG for gene induction, ATCC Trace Mineral Supplement, and glycolate.
Similarly, other aspects of the medium, and growth conditions of the cells of the invention may be optimized through routine experimentation. For example, pH and temperature are non- limiting examples of factors which can be optimized. In some embodiments, factors such as choice of media, media supplements, and temperature can influence production levels of a product, such as a terpenoid and/or steviol glycoside,. In some embodiments the concentration and amount of a supplemental component may be optimized. In some embodiments, how often the media is supplemented with one or more supplemental components, and the amount of time that the media is cultured before harvesting a product, such as a terpenoid and/or steviol glycoside, can be optimized.
The liquid cultures used to grow cells associated with the invention can be housed in any of the culture vessels known and used in the art. In some embodiments large scale production in an aerated reaction vessel such as a stirred tank reactor can be used to produce large quantities of product, such as a terpenoid and/or steviol glycoside, that can be recovered from the cell culture. In some embodiments, the terpenoid is recovered from the gas phase of the cell culture, for example by adding an organic layer such as dodecane to the cell culture and recovering the terpenoid from the organic layer. In some embodiments, the terpenoid is recovered from the of the cell culture, for example by adding a polymeric resin to the cell culture and recovering the terpenoid from the polymer by solvent extraction.
The invention also encompasses the chemical synthesis for the conversion of microbially produced steviol to steviol glycosides (Figure 2). The diterpenoid steviol can be converted to stevioside and rebaudioside A using multi-step chemical assembly of sugar moiety into steviol backbone. More specifically the chemical synthesis consists of following steps, as shown in Figure 2. A trimethylsilyl (TMS) protected at C19 COOH group of the steviol is synthesized from the microbially derived steviol. Tri-glucosylation at the C13-OH position of the steviol is performed using protected -Glc- -Glc(2→l)- -Glc(3→l) group. This is followed by a deprotection of the TMS and coupling of a protected mono β-Glc-Br moiety. The final deprotection removes all of the protecting groups to produce rebaudioside A.
In another aspect, the invention involves making a product containing a terpenoid selected from kaurene, a steviol, or a steviol glycoside. The method comprises increasing terpenoid production in a cell that produces one or more terpenoids by controlling the accumulation of indole in the cell or in a culture of the cells, and then recovering the terpenoid from the cell. The cell expresses an endogenous MVA or MEP pathway, and may overexpress one or more components of said pathway as described herein, to maximize production of kaurene, steviol, or steviol glycoside. Optionally, the method may further comprise conducting one or more chemical or enzymatic steps on the recovered terpenoid to produce a derivative of the terpenoid. The recovered terpenoid or the terpenoid prepared through one or more chemical or enzymatic steps is then incorporated into a product. In various embodiments, the cell is a bacterial cell such as E. coli or B. subtilis, or other cell disclosed herein, including yeast (e.g., Saccharomyces or Pichia pastoris), algal and plant cells.
The step of controlling the accumulation of indole in the cell or in a culture of the cells may be conducted through strain construction, and/or physically during culture as described herein. For example, the cell may be constructed to express functional components of an "upstream" MEP pathway, and one or more components of a "downstream" terpenoid synthesis pathway. The upstream and downstream pathways may be balanced to control indole accumulation, using a variety of genetic tools, including but not limited to selecting a gene copy number for one or more upstream or downstream pathway enzymes; increasing or decreasing the expression level of the upstream and downstream pathway genes (as individual genes or as operons) using promoters with different or similar strengths and/or modifications to ribosomal binding sites; replacing native genes in the downstream or upstream pathway with heterologous genes coding for homologous enzymes; codon-optimization of one or more heterologous enzymes in the upstream or downstream pathway; amino acid mutations in one or more genes of the downstream and/or upstream pathway; and modifying the order of upstream and downstream pathway genes in a heterologous operon.
In some embodiments, the cell comprises at least one additional copy of at least one of dxs, idi, ispD, and ispF, which in some embodiments is a heterologous dxs-idi-ispDF operon.
The accumulation of indole can be a proxy for the efficiency of terpenoid production, and thus the genetic elements may provide for accumulation of indole in the culture at less than 100 mg/L, or in other embodiments at less than 50 mg/L, at less than 10 mg/L, or at less than 1 mg/L.
In these or other embodiments, accumulation of indole in the cell or in a culture of the cells is controlled by modifying or regulating the indole pathway, or by removing the accumulated indole from the cell culture through chemical methods, including the use of one or more absorbents or scavengers. In various embodiments, the amount of indole in the culture is continuously or intermittently monitored.
In various embodiments, the terpenoid is one or more of steviobioside, stevioside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, and dulcoside A, which may be produced in accordance with pathways described herein. Generally, the pathway is constructed at least in-part in a microbial system, employing an upstream MEP pathway, and at least one, two, or three or more components of a downstream terpenoid synthesis pathway. For example, the cell may express a copalyl diphosphate synthase (CPS) enzyme, a kaurene synthase (KS) enzyme, and a GGPPS enzyme. In some embodiments, the cell may further express a kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme. In still other embodiments, the cell expresses one or more UDP- glycosyltransferases (UGTs) or a catalytically active portion(s) thereof. Exemplary UGTs include UDP-glycosyltransferase (UGT) enzyme(s) from Stevia (e.g. Stevia rebaudiana
Bertoni), or catalytically active portion(s), optionally expressed together on an operon. The UGTs may be expressed from a plasmid or integrated into the host genome.
Optionally, glycosyltransferase steps may take place ex vivo after recovery of the terpenoid substrate from cells.
The terpenoid produced by the method is incorporated into a product, such as a food product or beverage, where the terpenoid is a taste enhancer or bitter blocker. Exemplary products include dessert, yogurt, confectionary, sauce, pickle, delicacy, sweet corn, bread, biscuit, or soft drink. Other products include carbonated or non-carbonated drinks (including low-calorie beverages), cordials, milk, soy, mineral drink, canned fruit, jam, juice, ice cream, dietary product (e.g., low calorie products packaged for weight loss or weight control), cake, biscuit, pastry, dessert, sugar free beer, alcoholic beverage, topping, sauce, chutney, spread, cereal, muesli bar, and confectionaries.
Examples
METHODS
Strains, plasmids, oligonucleotides and genes
E coli K12MG1655 A(recA,endA) and E coli K 12MG 1655A(recA,endA)ED3 strains were used as the host strain of karuene strain construction. The sequences of geranylgeranyl pyrophosphate synthase (GGPPS^Copalyl pyrophosphate synthase (C), and Karuene Synthase (K) were obtained from Taxus canadensis and Stevia rebaudiana (Genbank accession codes: AF081514, AAB87091 and AF097311). Genes were custom- synthesized (from a commercial vendor) to incorporate E. coli translation codon and removal of restriction sites for cloning purposes.
Construction of MEP pathway (dxs-idi-idpDF operon) (15)
dxs-idi-ispDF operon was initially constructed by cloning each of the genes from the genome of E coli K12 MG1655 using the primers dxs(s), dxs(a), idi(s), idi(a), ispDF(s) and ispDFI(a) under pET21C+ plasmid with T7 promoter (p20T7MEP). Using the primers dxsidiispDFNcol (s) and dxsidiispDFKpnl(a) dxs-idi-ispDF operon was sub-cloned into pTrcHis2B (Invitrogen) plasmid after digestion with Ncol and Kpnl for pTrcMEP plasmid (p20TrcMEP). p20TrcMEP plasmid digested with Mlul and Pmel and cloned into Mlul and Pmel digested p ACYC 184-melA(P2A) plasmid to construct p 1 OTrcMEP plasmid. pTrcMEP plasmid digested with BstZ17I and Seal and cloned into PvuII digested pCL1920 plasmid to construct p5TrcMEP plasmid.
Construction of Kaurene pathway (KCG).
The downstream kaurene pathway (KCG) was constructed by cloning PCR fragments of
KS, CPS and GGPPS into the Ncol - Xhol, Xhol - EcoRl and EcoRl - Sail sites of pTrcHIS2B plasmid to create p20TrcKCG using the primers KSNcoI(s), KSXhoI(a), CPSXhoI(s),
CPSEcoRI(a), GGPPSEcoRI(s) and GGPPSSall(a). p5T7KCG was constructed by subcloning the Ncol/Sall digested KCG operon from p20TrcKCG into Ncol/Sall digested pCL1920T7 plasmid.
Construction of chromosomal integration MEP pathway plasmids (15) For constructing the plasmids with FRP-Km-FRP cassette for amplifying the sequence for integration, p20T7MEP was digested with Xhol/ScaL FRP-Km-FRP cassette was amplified from the Km cassette with FRP sequence from pkD13 plasmid using the primers
KmFRPXhoI(s) and KmFRPScal(a). The amplified DNA was digested with Xhol/Scal and cloned into the Xhol/Scal digested p20T7MEP plasmid (p20T7MEPKmFRP). Similarly the p20TrcMEP plasmid was digested with Sacl/Scal and the amplified DNA using the primers KmFRPSacI(s) and KmFRPScal(a) was digested, cloned into the p20TrcMEP plasmid
(p20TrcMEPKm-FRP). Chromosomal integration of the MEP pathway cassette (Laclq-MEP-FRP-Km-
FRP) cassette
The MEP pathways constructed under the promoters T7 and Trc were localized to the ara operon region in the chromosome with the Kan marker. The PCR fragments were amplified from p20T7MEPKmFRP and p20TrcMEPKm-FRP using the primers IntT7T5(s), IntTrc(s) and Int(a) and then electroporated into E. coli MG1655 recA-end- and E. coli MG1655 recA-end- EDE3 cells for chromosomal integration through the λ Red recombination technique. The site specific localization was confirmed and the Km marker was removed through the action of the FLP recombinase after successful gene integration. Culture growth for screening the kaurene production
Single transformants of pre-engineered E. coli strains harboring the appropriate plasmid with upstream (MEP), downstream kaurene pathway were cultivated for 18h at 30°C in Luria- Bertani (LB) medium (supplemented with appropriate antibiotics, 100 mg/mL carbenecilin, 34 mg/mL chloramphenicol, 25 mg/L kanamycin or 50 mg/L spectinomycin). For small scale cultures to screen the engineered strains, these preinnoculum were used to seed fresh 2-mL defined feed medium containing 0.5% yeast extract and 20% (v/v) dodecane (13.3 g/L ΚΗ2Ρ04, 4 g/L (NH4)2HP04, 1.7 g/L citric acid, 0.0084 g/L EDTA, 0.0025 g/L CoCl2, 0.015 g/L MnCl2, 0.0015 g/L CuCl2, 0.003 g/L H3B03, 0.0025 g/L Na2Mo04, 0.008 g/L Zn(CH3COO)2, 0.06 g/L Fe(III) citrate, 0.0045 g/L thiamine, 1.3 g/L MgS04, 10 g/L glycerol, 5 g/L yeast extract, pH 7.0). The culture was maintained with appropriate antibiotics and 100 mM IPTG for gene induction at 22 °C for 5 days. GC-MS analysis of kaurene
For analysis of kaurene accumulation from small scale culture, 1.5 mL of the culture was vortexed with lmL hexane for 30 min. The mixture was centrifuged to separate the organic layer. For bioreactor 1 uL of the dodecane layer was diluted to 200 uL using hexane. luL of the hexane layer was analyzed by GC-MS (Varian saturn 3800 GC attached to a Varian 2000 MS). The sample was injected into a HP5ms column (30m x 250 uM x 0.25 uM thickness) (Agilent Technologies USA). Helium (ultra purity) at a flow rate 1.0 ml/min was used as a carrier gas. The oven temperature was first kept constant at 50 °C for 1 min, and then increased to 220 °C at the increment of 10 °C/min, and finally held at this temperature for 10 min. The injector and transfer line temperatures were set at 200 °C and 250 °C, respectively. Pure taxadiene was used as a standard for the quantitative measurement of kaurene production from engineered strains.
Example 1: Engineering Karuene biosynthesis in E. coli.
The upstream MEP pathway module, dxs-idi-ispdF, was cloned under the control of two synthetic promoters with low (Trc) and high (T7) strength. The MEP pathway is further localized into the chromosome of the E. coli MG1655 recA-EndA- strain for the overproduction of the upstream isoprenoid metabolites and downstream kaurene. The putative downstream pathway for the biosynthesis of kaurene, GPPP synthase (G), Copalyl pyrophosphate synthase (C), and Karuene Synthase (K), was cloned under two promoters (Trc and T7) using a 20 copy (p20Trc-KCG) and 5 copy plasmid (p5T7-KCG). The downstream pathways was transferred into the upstream chromosomal MEP pathway engineered strains. A total of 4 strains were constructed with varying upstream and downstream pathway to understand the variation in kaurene production corresponding to the pathway strengths. Fig. 3B summarizes the details of strain construction and results of kaurene accumulation from engineered E. coli strains. Clearly, the balancing of the upstream and downstream pathway is key for the high accumulation of kaurene. This is the first example of microbial production of the steviol glycoside precursor scaffold kaurene.
Example 2: Metabolite Indole accumulation inversely correlates with karuene.
Metabolomic analysis of the engineered strains identified the accumulation of the metabolite indole that correlated strongly with pathway expression levels and kaurene production (Fig. 4). The corresponding peaks in the gas chromatography- mass spectrometry (GC-MS) chromatogram was identified as indole and kaurene.
Figure imgf000034_0001
Table 2. Details of plasmids constructed for the study
Table 3. Details of the primers used for the cloning of plasmids, and chromosomal delivery of the MEP pathway.
Primer Name Sequences
CGGCATATGAGTTTTGATATTGCCAAATACCCG (SEQ ID dxsNdel(s)
NO: 17)
CGGCTAGCTTATGCCAGCCAGGCCTTGATTTTG (SEQ ID dxsNhel(a)
NO: 18)
CGCGGCTAGCGAAGGAGATATACATATGCAAACGGAACACG
idiNhel (s)
TCATTTTATTG (SEQ ID NO: 19)
CGGAATTCGCTCACAACCCCGGCAAATGTCGG (SEQ ID idiEcoRI(a)
NO:20)
GCGAATTCGAAGGAGATATACATATGGCAACCACTCATTTG
ispDFEcoRI(s)
GATGTTTG (SEQ ID NO:21)
GCGCTCGAGTCATTTTGTTGCCTTAATGAGTAGCGCC (SEQ ispDFXhoI(a)
ID NO:22)
TAAACCATGGGTTTTGATATTGCCAAATACCCG (SEQ ID dxsidiispDFNcoI(s)
NO:23)
CGGGGTACCTCATTTTGTTGCCTTAATGAGTAGCGC (SEQ ID dxsidiispDFKpnl(a)
NO:24)
CGGCTCGAGTCATTTTGTTGCCTTAATGAGTAGCGC (SEQ ID dxsidiispDFXhoI(a)
NO:25)
CGTAACCGGTGCCTCTGCTAACCATGTTCATGCCTTC (SEQ ID
T5AgeI(s)
NO:26)
T5NheI(a) CTCCTTCGCTAGCTTATGCCAGCC (SEQ ID NO:27)
CGTAGAATTCAGAAGGAGATATACATATGTTTGATTTCAATG
GGPPSEcoRI(s)
AATATATGAAAAGTAAGGC (SEQ ID NO:28)
GATGGTCGACTCACAACTGACGAAACGCAATGTAATC (SEQ
GGPPSSall(a)
ID NO:29)
KSNcol(s) ACCATGGCTCTGTCTCTGTGCATT (SEQ ID NO:30)
KSXhol(a) TCTCGAGTTAACGTTGTTCTTCGTTTTCG (SEQ ID NO:31)
ACTCGAGAAGAAGGAGATATACATATGAAGACTGG
CPSXhol(s)
(SEQ ID NO:32) TGAATTCTCAGATTACGATTTCAAATACTTTGG (SEQ ID
CPSEcoRI(a)
NO:33)
GACGCTCGAGGAGCAATAACTAGCATAACCCCTTGGGGCCT
KmFRPXhoI(s) CTAAACGGGTCTTGAGGGGTTTTTTGCTTGTGTAGGCTGGAG
CTGCTTCG (SEQ ID NO: 34)
GACGAGTACTGAACGTCGGAATTGATCCGTCGAC (SEQ ID
KmFRPScal(a)
NO:35)
GACGGAGCTCGAGCAATAACTAGCATAACCCCTTGGGGCCT
KmFRPSacI(s) CTAAACGGGTCTTGAGGGGTTTTTTGCTTGTGTAGGCTGGAG
CTGCTTCG (SEQ ID NO: 36)
IntT7T5(s)
TTAATTGCGTTGCGCTCACTG (SEQ ID NO:37)
IntTrc(s)
ATCCGCTTACAGACAAGCTGTG (SEQ ID NO:38)
TTAGCGACGAAACCCGTAATACACTTCGTTCCAGCGCAGCC
Int(a)
GACGTCGGAATTGATCCGTCGAC (SEQ ID NO:39)
Table 4. Exemplary protein sequences. Enzyme sequences in accordance with aspects of the invention may be as defined below. Alternatively, the enzymes may be optimized through processes and parameters as described herein, and generally producing amino acid sequences that are at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to the amino acid sequences shown below, including with respect to the full length sequence or a catalytically active truncated sequence.
GGPP synthase (Γ. canadensis: AF081514) - SEQ ID NO:l
MFDFNEYMKSKAVAVDAALDKAIPLEYPEKIHESMRYSLLAGGKRVRPALCIAACE
LVGGSQDLAMPTACAMEMIHTMSLIHDDLPCMDNDDFRRGKPTNHKVFGEDTAVL
AGDALLSFAFEHIAVATSKTVPSDRTLRVISELGKTIGSQGLVGGQVVDITSEGDANV
DLKTLEWIHIHKTAVLLECSVVSGGILGGATEDEIARIRRYARCVGLLFQVVDDILDV
TKSSEELGKTAGKDLLTDKATYPKLMGLEKAKEFAAELATRAKEELSSFDQIKAAPL
LGLADYIAFRQN
GGPP synthase (Stevia rebaudiana: ABD92926) - SEQ ID NO:2
MALVNPTALFYGTSIRTRPTNLLNPTQKLRPVSSSSLPSFSSVSAILTEKHQSNPSENN
NLQTHLETPFNFDSYMLEKVNMVNEALDASVPLKDPIKIHESMRYSLLAGGKRIRPM
MCIAACEIVGGNILNAMPAACAVEMIHTMSLVHDDLPCMDNDDFRRGKPISHKVYG
EEMAVLTGDALLSLSFEHIATATKGVSKDRIVRAIGELARSVGSEGLVAGQVVDILSE
GADVGLDHLEYIHIHKTAMLLESSVVIGAIMGGGSDQQIEKLRKFARSIGLLFQVVDD
ILDVTKSTEELGKTAGKDLLTDKTTYPKLLGIEKSREFAEKLNKEAQEQLSGFDRRK
AAPLIALANYNAYRQN
Copalyl pyrophosphate synthase {Stevia rebaudiana: AAB87091) - SEQ ID NO:3
MKTGFISPATVFHHRISPATTFRHHLSPATTNSTGIVALRDINFRCKAVSKEYSDLLQK
DEASFTKWDDDKVKDHLDTNKNLYPNDEIKEFVESVKAMFGSMNDGEINVSAYDT
AWVALVQDVDGSGSPQFPSSLEWIANNQLSDGSWGDHLLFSAHDRIINTLACVIALT
SWNVHPSKCEKGLNFLRENICKLEDENAEHMPIGFEVTFPSLIDIAKKLNIEVPEDTPA
LKEIYARRDIKLTKIPMEVLHKVPTTLLHSLEGMPDLEWEKLLKLQCKDGSFLFSPSS
TAFALMQTKDEKCLQYLTNIVTKFNGGVPNVYPVDLFEHr VVDRLQRLGIARYFK
SEIKDCVEYINKYWTKNGICWARNTHVQDIDDTAMGFRVLRAHGYDVTPDVFRQFE
KDGKFVCFAGQSTQAVTGMFNVYRASQMLFPGERILEDAKKFSYNYLKEKQSTNEL
LDKWIIAKDLPGEVGYALDIPWYASLPRLETRYYLEQYGGEDDVWIGKTLYRMGYV
SNNTYLEMAKLDYNNYVAVLQLEWYTIQQWYVDIGIEKFESDNIKSVLVSYYLAAA
SIFEPERSKERIAWAKTTILVDKITSIFDSSQSSKEDITAFIDKFRNKSSSKKHSINGEPW
HEVMVALKKTLHGFALDALMTHSQDIHPQLHQAWEMWLTKLQDGVDVTAELMVQ
MINMTAGRWVSKELLTHPQYQRLSTVTNSVCHDITKLHNFKENSTTVDSKVQELVQ
LVFSDTPDDLDQDMKQTFLTVMKTFYYKAWCDPNTINDHISKVFEIVI Kaurene synthase (Stevia rebaudiana AF097311_1) - SEQ ID NO:4
MNLSLCIASPLLTKSNRPAALSAIHTASTSHGGQTNPTNLIIDTTKERIQKQFKNVEISV
SSYDTAWVAMVPSPNSPKSPCFPECLNWLINNQLNDGSWGLVNHTHNHNHPLLKDS
LSSTLACIVALKRWNVGEDQINKGLSFIESNLASATEKSQPSPIGFDIIFPGLLEYAKNL
DINLLSKQTDFSLMLHKRELEQKRCHSNEMDGYLAYISEGLGNLYDWNMVKKYQM
KNGSVFNSPSATAAAFINHQNPGCLNYLNSLLDKFGNAVPTVYPHDLFIRLSMVDTIE
RLGISHHFRVEIKNVLDETYRCWVERDEQIFMDVVTCALAFRLLRINGYEVSPDPLAE
ITNELALKDEYAALETYHASHILYQEDLSSGKQILKSADFLKEIISTDSNRLSKLIHKE
VENALKFPINTGLERINTRRNIQLYNVDNTRILKTTYHSSNISNTDYLRLAVEDFYTCQ
SIYREELKGLERWVVENKLDQLKFARQKTAYCYFSVAATLSSPELSDARISWAKNGI
LTTVVDDFFDIGGTIDELTNLIQCVEKWNVDVDKDCCSEHVRILFLALKDAICWIGDE
AFKWQARDVTSHVIQTWLELMNSMLREAIWTRDAYVPTLNEYMENAYVSFALGPI
VKPAIYFVGPKLSEEIVESSEYHNLFKLMSTQGRLLNDIHSFKREFKEGKLNAVALHL
SNGESGKVEEEVVEEMMMMIKNKRKELMKLIFEENGSIVPRACKDAFWNMCHVLN
FFYANDDGFTGNTILDTVKDIIYNPLVLVNENEEQR
Kaurene oxidase {Stevia rebaudiana: ABA42921) - SEQ ID NO:5
MDAVTGLLTVPATAITIGGTAVALAVALIFWYLKSYTSARRSQSNHLPRVPEVPGVP
LLGNLLQLKEKKPYMTFTRWAATYGPIYSIKTGATSMVVVSSNEIAKEALVTRFQSIS
TRNLSKALKVLTADKTMVAMSDYDDYHKTVKRHILTAVLGPNAQKKHRIHRDIMM
DNISTQLHEFVKNNPEQEEVDLRKIFQSELFGLAMRQALGKDVESLYVEDLKITMNR
DEIFQVLVVDPMMGAIDVDWRDFFPYLKWVPNKKFENTIQQMYIRREAVMKSLIKE
HKKRIASGEKLNSYIDYLLSEAQTLTDQQLLMSLWEPIIESSDTTMVTTEWAMYELA
KNPKLQDRLYRDIKSVCGSEKITEEHLSQLPYITAIFHETLRRHSPVPIIPLRHVHEDTV
LGGYHVPAGTELAVNIYGCNMDKNVWENPEEWNPERFMKENETIDFQKTMAFGGG
KRVCAGSLQALLTASIGIGRMVQEFEWKLKDMTQEEVNTIGLTTQMLRPLRAIIKPRI
Ent-kaurenoic acid 13-hydroxylase {Stevia rebaudiana: ACD93722) - SEQ ID NO:6
MIQVLTPILLFLIFFVFWKVYKHQKTKINLPPGSFGWPFLGETLALLRAGWDSEPERF
VRERIKKHGSPLVFKTSLFGDRFAVLCGPAGNKFLFCNENKLVASWWPVPVRKLFG
KSLLTIRGDEAKWMRKMLLSYLGPDAFATHYAVTMDVVTRRHIDVHWRGKEEVN
VFQTVKLYAFELACRLFMNLDDPNHIAKLGSLFNIFLKGIIELPIDVPGTRFYSSKKAA
A AIRIELKKLIK ARKLELKEGKAS S S QDLLS HLLTSPDENGMFLTEEEIVDNILLLLF A
GHDTSALSITLLMKTLGEHSDVYDKVLKEQLEISKTKEAWESLKWEDIQKMKYSWS
VICEVMRLNPPVIGTYREALVDIDYAGYTIPKGWKLHWSAVSTQRDEANFEDVTRFD
PSRFEGAGPTPFTFVPFGGGPRMCLGKEFARLEVLAFLHNIVTNFKWDLLIPDEKIEY
DPMATPAKGLPIRLHPHQV
Taxus NADPHrcytochrome P450 reductase {Taxus cuspidate: AY571340) - SEQ ID NO:7
MQANSNTVEGASQGKSLLDISRLDHIFALLLNGKGGDLGAMTGSALILTENSQNLMI
LTTALAVLVACVFFFVWRRGGSDTQKPAVRPTPLVKEEDEEEEDDSAKKKVTIFFGT
QTGTAEGFAKALAEEAKARYEKAVFKVVDLDNYAADDEQYEEKLKKEKLAFFMLA
TYGDGEPTDNAARFYKWFLEGKEREPWLSDLTYGVFGLGNRQYEHFNKVAKAVDE
VLIEQGAKRLVPVGLGDDDQCIEDDFTAWREQVWPELDQLLRDEDDEPTSATPYTA
AIPEYRVEIYDSVVSVYEETHALKQNGQAVYDIHHPCRSNVAVRRELHTPLSDRSCIH
LEFDISDTGLIYETGDHVGVHTENSIETVEEAAKLLGYQLDTIFSVHGDKEDGTPLGG
SSLPPPFPGPCTLRTALARYADLLNPPRKAAFLALAAHASDPAEAERLKFLSSPAGKD EYSQWVTASQRSLLEIMAEFPSAKPPLGVFFAAIAPRLQPRYYSISSSPRFAPSRIHVTC
ALVYGPSPTGRfflKGVCSNWMKNSLPSEETHDCSWAPVFVRQSNFKLPADSTTPIVM
VGPGTGFAPFRGFLQERAKLQEAGEKLGPAVLFFGCRNRQMDYIYEDELKGYVEKG
ILTNLIVAFSREGATKEYVQHKMLEKASDTWSLIAQGGYLYVCGDAKGMARDVHR
TLHTIVQEQESVDSSKAEFLVKKLQMDGRYLRDRV
Stevia NADPH: cytochrome P450 reductase (Stevia rebaudiana: ABB88839) - SEQ ID NO:8
MQSDSVKVSPFDLVSAAMNGKAMEKLNASESEDPTTLPALKMLVENRELLTLFTTS
FA VLIGCLVFLMWRRS S S KKLVQDP VPQ VIV VKKKEKESEVDDGKKKVS IF YGTQTG
TAEGFAKALVEEAKVRYEKTSFKVIDLDDYAADDDEYEEKLKKESLAFFFLATYGD
GEPTDNAANFYKWFTEGDDKGEWLKKLQYGVFGLGNRQYEHFNKIAIVVDDKLTE
MGAKRLVPVGLGDDDQCIEDDFTAWKELVWPELDQLLRDEDDTSVTTPYTAAVLE
YRVVYHDKPADSYAEDQTHTNGHVVHDAQHPSRSNVAFKKELHTSQSDRSCTHLEF
DISHTGLSYETGDHVGVYSENLSEVVDEALKLLGLSPDTYFSVHADKEDGTPIGGAS
LPPPFPPCTLRDALTRYADVLSSPKKVALLALAAHASDPSEADRLKFLASPAGKDEY
AQWrVANQRSLLEVMQSFPSAKPPLGVFFAAVAPRLQPRYYSISSSPKMSPNRIHVTC
ALVYETTPAGRIHRGLCSTWMKNAVPLTESPDCSQASIFVRTSNFRLPVDPKVPVIMI
GPGTGLAPFRGFLQERLALKESGTELGSSIFFFGCRNRKVDFIYEDELNNFVETGALSE
LIVAFSREGTAKEYVQHKMSQKASDr KLLSEGAYLYVCGDAKGMAKDVHRTLHT
IVQEQGSLDSSKAELYVKNLQMSGRYLRDVW
UDP-glucosyltransferase-1 {Stevia rebaudiana: AAM53963) - SEQ ID NO:9
MATSDSIVDDRKQLHVATFPWLAFGHILPFLQLSKLIAEKGHKVSFLSTTRNIQRLSS
HISPLINVVQLTLPRVQELPEDAEATTDVHPEDIQYLKKAVDGLQPEVTRFLEQHSPD
WIIYDFTHYWLPSIAASLGISRAYFCVITPWTIAYLAPSSDAMINDSDGRTTVEDLTTP
PKWFPFPTKVCWRKHDLARMEPYEAPGISDGYRMGMVFKGSDCLLFKCYHEFGTQ
WLPLLETLHQVPVVPVGLLPPEIPGDEKDETWVSIKKWLDGKQKGSVVYVALGSEA
LVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTS
WAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPLFGDQPLNARLLEDKQVGI
EIPRNEEDGCLTKESVARSLRSVVVENEGEIYKANARELSKIYNDTKVEKEYVSQFV
DYLEKNARAVAIDHES
UDP-glucosyltransferase-2 {Stevia rebaudiana: AAR06921) - SEQ ID NO:10
MPISDINAGSHILVFPYPAQGHMLTLLDLTHQLAIRNLTITILVTPKNLPTISPLLAAHP
TTVSALLLPLPPHPAIPSGIENVKDLPNDAFKAMMVALGDLYNPLRDWFRNQPNPPV
AIISDFFLGWTHHLAVELGIRRYTFSPSGALALSVIFSLWRYQPKRIDVENEKEAIKFP
KIPNSPEYPWWQLSPIYRSYVEGDPDSEFIKDGFLADIASWGIVINSFTELEQVYVDHL
KHELGHDQVFAVGPLLPPGDKTSGRGGSSSNDVLSWLDTCADRTVVYVCFGSQMV
LTNGQMEVVALGLEKSRVKFVWSVKEPTVGHEAANYGRVPPGFEDRVSGRGLVIR
GWVPQVAILSHDSVGVFLTHCGWNSVMEAVAAEVLMLTWPMSADQFSNATLLHEL
KVGIKVCEGSNIVPNSDELAELFSKSLSDETRLERKRVKEFAKSAKEAVGPKGSSVGE
LERLVDNLSL
UDP-glucosyltransferase-3 {Stevia rebaudiana: AAR06920) - SEQ ID NO:ll
MAEQQKIKKSPHVLLIPFPLQGHINPFIQFGKRLISKGVKTTLVTTIHTLNSTLNHSNTT TTSIEIQAISDGCDEGGFMSAGESYLETFKQVGSKSLADLIKKLQSEGTTIDAIIYDSMT EWVLDVAIEFGIDGGSFFTQACVVNSLYYHVHKGLISLPLGETVSVPGFPVLQRWET
PLILQNHEQIQSPWSQMLFGQFANIDQARWVFTNSFYKLEEEVIEWTRKIWNLKVIGP
TLPSMYLDKRLDDDKDNGFNLYKANHHECMNWLDDKPKESVVYVAFGSLVKHGP
EQVEEITRALIDSDVNFLWVIKHKEEGKLPENLSEVIKTGKGLIVAWCKQLDVLAHES
VGCFVTHCGFNSTLEAISLGVPVVAMPQFSDQTTNAKLLDEILGVGVRVKADENGIV
RRGNLASCIKMIMEEERGVIIRKNAVKWKDLAKVAVHEGGSSDNDIVEFVSELIKA
UDP-glucosyltransferase-4 (Stevia rebaudiana: AAR06917) - SEQ ID NO:12
MSPKMVAPPTNLHFVLFPLMAQGHLVPMVDIARILAQRGATVTIITTPYHANRVRPV
ISRAIATNLKIQLLELQLRSTEAGLPEGCESFDQLPSFEYWKNISTAIDLLQQPAEDLLR
ELSPPPDCIISDFLFPWTTDVARRLNIPRLVFNGPGCFYLLCIHVAITSNILGENEPVSSN
TERVVLPGLPDRIEVTKLQIVGSSRPANVDEMGSWLRAVEAEKASFGIVVNTFEELEP
EYVEEYKTVKDKKMWCIGPVSLCNKTGPDLAERGNKAAITEHNCLKWLDERKLGS
VLYVCLGSLARISAAQAIELGLGLESINRPFr CVRNETDELKTWFLDGFEERVRDRG
LIVHGWAPQVLILSHPTIGGFLTHCGWNSTIESITAGVPMITWPFFADQFLNEAFIVEV
LKIGVRIGVERACLFGEEDKVGVLVKKEDVKKAVECLMDEDEDGDQRRKRVIELAK
MAKIAMAEGGSSYENVSSLIRDVTETVRAPH
UDP-glucosyltransferase-5 {Stevia rebaudiana: AAN40684) - SEQ ID NO:13
MSLKGNDKELHLVMFPFFAFGHITPFVQLSNKISSLYPGVKITFLAASASVSRIETMLN
PSTNTKVIPLTLPRVDGLPEGVENTADASPATIGLLVVAIDLMQPQIKTLLANLKPDF
VIFDFVHWWLPEIASELGIKTIYFSVYMANIVMPSTSKLTGNKPSTVEDIKALQQSDGI
PVKTFEAISLMNVFKSFHDWMDKCINGCNLMLIKSCREMEGSRIDDVTKQSTRPVFLI
GPVVPEPHSGELDETWANWLNRFPAKSVIYCSFGSETFLTDDQIRELALGLELTGLPF
FLVLNFPANVDKSAELKRTLPDGFLERVKDKGIVHSGWVQQRHILAHDSVGCYVFH
AGYGSVIEGLVNDCQLVMLPMKVDQFTNSKVIALELKAGVEVNRRDEDGYFGKDD
VFEAVESVMMDTENEPAKSIRENHRKLKEFLQNDEIQKKYIADFVENLKAL
UDP-glucosyltransferase-6 {Stevia rebaudiana: ACE87855) - SEQ ID NO:14
MATSDSIVDDRKQLHVATFPWLAFGHILPYLQLSKLIAEKGHKVSFLSTTRNIQRLSS
HISPLINVVQLTLPRVQELPEDAEATTDVHPEDIPYLKKASDGLQPEVTRFLEQHSPD
WIIYDYTHYWLPSIAASLGISRAHFSVTTPWAIAYMGPSADAMINGSDGRTTVEDLTT
PPKWFPFPTKVCWRKHDLARLVPYKAPGISDGYRMGLVLKGSDCLLSKCYHEFGTQ
WLPLLETLHQVPVVPVGLLPPEVPGDEKDETWVSIKKWLDGKQKGSVVYVALGSEV
LVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTS
WAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPIFGDQPLNARLLEDKQVGI
EIPRNEEDGCLTKESVARSLRSVVVEKEGEIYKANARELSKIYNDTKVEKEYVSQFV
DYLEKNTRAVAIDHES References
1. M. Sharma, N. K. Thakral, S. Thakral, Natural Product Radiance 8, 181 (2009).
2. M. C. Carakostas, L. L. Curry, A. C. Boileau, D. J. Brusick, Food Chem Toxicol 46 Suppl 7, SI (Jul, 2008).
3. S. R. Mishra P., Kumar U. and Prakash V, Global Journal of Biotechnology &
Biochemistry 5, 62 (2010).
4. S. D. Singh, G. P. Rao, Sugar Tech 7, 17 (2005).
5. P. K. Ajikumar et al. , Mol Pharm 5, 167 (Mar- Apr, 2008).
6. M. C. Carakostas, L. L. Curry, A. C. Boileau, D. J. Brusick, Food and Chemical
Toxicology 46, SI (2008).
7. C. Ulbricht et al., Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents) 8, 113.
8. J. M. C. Geuns,
http://www. eustas. org/Steviol_glycosides_summary_application.pdfSteviol, EUSTAS, (2007).
9. K. E. Tyo, H. S. Alper, G. N. Stephanopoulos, Trends Biotechnol 25, 132 (Mar, 2007).
10. A. S. Richman, M. Gijzen, A. N. Starratt, Z. Yang, J. E. Brandle, The Plant Journal 19,
411 (1999).
11. J. Geuns, Phy to chemistry 64, 913 (2003).
12. A. Richman et al., The Plant Journal 41, 56 (2005).
13. D. G. Gibson et al, Science 329, 52 (Jul 2, 2010).
14. V. E. Balderas-Hernandez et al. , Microb Cell Fact 8, 19 (2009).
15. Ajikumar, P. K., et al., Science. 330, 70-4 (Oct 2010)
Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention.
Accordingly, the foregoing description and drawings are by way of example only. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
All references disclosed herein are incorporated by reference in their entirety for the specific purpose mentioned herein.
What is claimed is:

Claims

Claims
1. A method comprising:
recombinantly expressing a copalyl diphosphate synthase (CPS), kaurene synthase (KS) and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in a cell that expresses an endogenous non-mevalonate pathway (MEP) or mevalonic acid pathway (MVA), and which optionally overexpresses one or more components of said pathway.
2. The method of claim 1, wherein the cell is a bacterial cell.
3. The method of claim 2, wherein the cell is an Escherichia coli cell.
4. The method of claim 2, wherein the cell is a Gram-positive cell.
5. The method of claim 4, wherein the cell is a Bacillus cell.
6. The method of claim 1, wherein the cell is a yeast cell.
7. The method of claim 6, wherein the yeast cell is a Sacchawmyces or Pichia cell.
8. The method of claim 6, wherein the yeast cell is a Yarrowia cell.
9. The method of claim 1, wherein the cell is an algal cell.
10. The method of claim 1, wherein the cell is a plant cell.
11. The method of claim 1, wherein the copalyl diphosphate synthase (CPS) enzyme is a Stevia enzyme. 12. The method of claim 11, wherein the copalyl diphosphate synthase is a Stevia rebaudiana Bertoni enzyme. The method of claim 1, wherein the kaurene synthase (KS) enzyme is a Stevia enzyme.
14. The method of claim 13, wherein the kaurene synthase is a Stevia rebaudiana Bertoni enzyme.
15. The method of any one of claims 1 to 14, wherein the GGPPS enzyme is a Taxus enzyme or a Stevia enzyme.
16. The method of claim 15, wherein the GGPPS enzyme is a Taxus canadenis enzyme.
17. The method of claim 15, wherein the GGPPS enzyme is a Stevia rebaudiana Bertoni enzyme.
18. The method of any one of claims 1 to 17, wherein the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP pathway are expressed from one or more plasmids.
19. The method of any one of claims 1 to 17, wherein the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP are incorporated into the genome of the cell.
20. The method of any one of claims 1 to 19, wherein the one or more components of the non-mevalonate (MEP) pathway is selected from the group consisting of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB.
21. The method of claim 20, wherein dxs, idi, ispD and ispF are overexpressed. 22. The method of claim 21, wherein dxs, idi, ispD and ispF are overexpressed on the operon dxs-idi-ispDF. The method of claim 20, wherein ispC, ispE, ispG and ispH are overexpressed.
24. The method of claim 23 wherein ispC, ispE, ispG and ispH are overexpressed on the operon ispC-ispE-ispG-ispH.
25. The method of any one of claims 1 to 24, wherein the gene encoding the copalyl diphosphate synthase (CPS) enzyme, the gene encoding the kaurene synthase (KS) enzyme and the gene encoding the GGPPS enzyme are expressed together on an operon. 26. The method of any one of claims 1 to 25, wherein the cell further expresses a kaurene oxidase (KO) or a catalytically active portion thereof and/or a kaurenoic acid 13 -hydroxylase (KAH) or a catalytically active portion thereof.
27. The method of claim 26, wherein the kaurene oxidase (KO), kaurenoic acid 13- hydroxylase (KAH), or catalytically active portion thereof is fused to a cytochrome P450 reductase enzyme or a catalytically active portion thereof.
28. The method of claim 26 or 27 wherein the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, and the gene encoding the kaurenoic acid 13- hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, are expressed together on an operon. 29. The method of claim 26 or 27 wherein the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, and the gene encoding the kaurenoic acid 13- hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, are expressed from one or more plasmids.
30. The method of claim 26 or 27 wherein the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, and the gene encoding the kaurenoic acid 13- hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion, are incorporated into the genome of the cell.
31. The method of any one of claims 1 to 30, wherein the cell further expresses one or more UDP-glycosyltransferases (UGTs) or a catalytically active portion thereof.
32. The method of claim 31, wherein the UDP-glycosyltransferase (UGT) enzyme(s) is a Stevia enzyme.
33. The method of claim 32, wherein the UDP-glycosyltransferase (UGT) enzyme(s) is a Stevia rebaudiana Bertoni enzyme.
34. The method of any one of claims 31 to 33, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are expressed together on an operon.
35. The method of any one of claims 31 to 33, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are expressed from one or more plasmids. 36. The method of any one of claims 31 to 33, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are incorporated into the genome of the cell.
37. The method of any one of claims 1 to 36, wherein the expression of the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme, the GGPPS enzyme and the one or more components of the MEP pathway are balanced to maximize production of the kaurene or a downstream product of kaurene.
38. The method of any one of claims 1 to 37, further comprising culturing the cell.
39. The method of any one of claims 1 to 38, wherein the cell produces kaurene.
40. The method of any one of claims 26 to 30, wherein the expression of the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme, the geranylgeranyl diphosphate synthase (GGPPS) enzyme, the kaurene oxidase (KO) synthase enzyme, kaurenoic acid 13 -hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme and the one or more components of the MEP pathway are balanced to maximize production of steviol.
41. The method of claim 40, further comprising culturing the cell.
42. The method of claim 40, wherein the cell produces steviol.
43. The method of any one of claims 37 to 42, further comprising recovering the kaurene, steviol or steviol glycosides from the cell culture.
44. The method of claim 43, wherein the kaurene, steviol or steviol glycosides is recovered from the gas phase.
45. The method of claim 43, wherein an organic layer or polymeric resin is added to the cell culture, and the kaurene, steviol or steviol glycosides is recovered from the organic layer or polymeric resin.
46. The method of any one of claims 43 to 45, wherein the steviol glycoside is Reb A.
47. A cell that expresses the non-mevalonic acid (MVA) pathway or expresses the non- mevalonate (MEP) pathway, and which optionally overexpresses one or more components of said pathway, and that recombinantly expresses a copalyl diphosphate synthase (CPS) enzyme, a kaurene synthase (KS) enzyme, a geranylgeranyl diphosphate synthase (GGPPS) enzyme, a kaurene oxidase (KO) enzyme or a catalytically active portion of KO fused to a cytochrome P450 reductase enzyme, and a kaurenoic acid 13-hydroxylase (KAH) enzyme or catalytically active portion of KAH fused to a cytochrome P450 reductase enzyme. 48. The cell of claim 47, wherein the cell is a bacterial cell.
49. The cell of claim 48, wherein the cell is an Escherichia coli cell.
50. The cell of claim 48, wherein the cell is a Gram-positive cell.
51. The cell of claim 48, wherein the cell is a Bacillus cell.
52. The cell of claim 47, wherein the cell is a yeast cell. 53. The cell of claim 52, wherein the yeast cell is a Saccharomyces or Pichia cell.
54. The cell of claim 52, wherein the yeast cell is a Yarrowia cell.
55. The cell of claim 47, wherein the cell is an algal cell.
56. The cell of claim 47, wherein the cell is a plant cell.
57. The cell of any one of claims 47 to 56, wherein the copalyl diphosphate synthase (CPS) enzyme is a Stevia enzyme.
58. The cell of claim 57, wherein the copalyl diphosphate synthase is a Stevia rebaudiana Bertoni enzyme.
59. The cell of any one of claims 47 to 58, wherein the kaurene synthase (KS) enzyme is a Stevia enzyme.
60. The cell of claim 59, wherein the kaurene synthase is a Stevia rebaudiana Bertoni enzyme.
61. The cell of any one of claims 47 to 60, wherein the GGPPS enzyme is a Taxus enzyme or a Stevia enzyme.
62. The cell of claim 61, wherein the GGPPS enzyme is a Taxus canadenis enzyme.
63. The cell of claim 61, wherein the GGPPS enzyme is a Stevia rebaudiana Bertoni enzyme.
64. The cell of any one of claims 47 to 63, wherein the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP pathway are expressed from one or more plasmids.
65. The cell of any one of claims 47 to 63, wherein the gene encoding the copalyl diphosphate synthase (CPS) enzyme and/or the gene encoding the kaurene synthase (KS) enzyme and/or the gene encoding the GGPPS enzyme and/or the genes encoding the one or more components of the MEP are incorporated into the genome of the cell.
66. The cell of any one of claims 47 to 65, wherein the one or more components of the non- mevalonate (MEP) pathway are selected from the group consisting of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA and ispB.
67. The cell of claim 66, wherein dxs, idi, ispD and ispF are overexpressed.
68. The cell of claim 67, wherein dxs, idi, ispD and ispF are overexpressed on the operon dxs-idi-ispDF.
69. The cell of claim 66, wherein ispC, ispE, ispG and ispH are overexpressed.
70. The cell of claim 69, wherein ispC, ispE, ispG and ispH are overexpressed on the operon ispC-ispE-ispG-ispH.
71. The cell of any one of claims 47 to 70, wherein the gene encoding the copalyl diphosphate synthase (CPS) enzyme, the gene encoding the kaurene synthase (KS) enzyme and the gene encoding the GGPPS enzyme are expressed together on an operon.
72. The cell of any one of claims 47 to 70, wherein the cell further expresses a kaurene oxidase (KO) or a catalytically active portion thereof and/or a kaurenoic acid 13 -hydroxylase (KAH) or a catalytically active portion thereof.
73. The cell of claim 72, wherein the kaurene oxidase (KO), kaurenoic acid 13 -hydroxylase (KAH), or catalytically active portion thereof is fused to a cytochrome P450 reductase enzyme or a catalytically active portion thereof.
74. The cell of claim 72 or 73, wherein the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion and the gene encoding the kaurenoic acid 13 -hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion are expressed together on an operon.
75. The cell of claim 72 or 73, wherein the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion and the gene encoding the kaurenoic acid 13 -hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion are expressed from one or more plasmids.
76. The cell of claim 72 or 73, wherein the gene encoding the kaurene oxidase (KO) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion and the gene encoding the kaurenoic acid 13 -hydroxylase (KAH) enzyme or catalytically active portion thereof or fusion thereof to a cytochrome P450 reductase enzyme or a catalytically active portion are incorporated into the genome of the cell.
77. The cell of any one of claims 47 to 76, wherein the cell further expresses one or more UDP-glycosyltransferases (UGTs) or a catalytically active portion thereof. 78. The cell of claim 77, wherein the UDP-glycosyltransferase (UGT) enzyme(s) is a Stevia enzyme.
79. The cell of claim 78, wherein the UDP-glycosyltransferase (UGT) enzyme(s) is a Stevia rebaudiana Bertoni enzyme.
80. The cell of any one of claims 77 to 79, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are expressed together on an operon. 81. The cell of any one of claims 77 to 80, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are expressed from one or more plasmids.
82. The cell of any one of claims 77 to 80, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are incorporated into the genome of the cell.
83. The cell of any one of claims 47 to 82, wherein the expression of the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme, the GGPPS enzyme and the one or more components of the MEP pathway are balanced to maximize production of the kaurene or a downstream product thereof.
84. The cell of claim 83, wherein the cell produces kaurene.
85. The cell of any one of claims 72 to 82, wherein the expression of the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme, the geranylgeranyl diphosphate synthase (GGPPS) enzyme, the kaurene oxidase (KO) synthase enzyme, kaurenoic acid 13- hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH fused to a cytochrome P450 reductase enzyme and the one or more components of the MEP pathway are balanced to maximize production of steviol. 86. The cell of claim 85, wherein the cell produces steviol.
87. A method for selecting a cell that exhibits enhanced production of kaurene, steviol or steviol glycosides, the method comprising:
creating or obtaining a cell that overexpresses one or more components of the mevalonic acid pathway (MVA) or non-mevalonate (MEP) pathway,
producing kaurene, steviol or steviol glycosides from the cell,
comparing the amount of kaurene, steviol or steviol glycosides produced from the cell to the amount of kaurene, steviol or steviol glycosides produced in a control cell, and
selecting a first improved cell that produces a higher amount of kaurene, steviol or steviol glycosides than a control cell, wherein a first improved cell that produces a higher amount of kaurene, steviol or steviol glycosides than the control cell is a cell that exhibits enhanced production of kaurene, steviol or steviol glycosides.
88. The method of claim 87, wherein the cell recombinantly expresses a copalyl diphosphate synthase (CPS) enzyme and/or a kaurene synthase (KS) enzyme.
89. The method of claim 87 or 88, wherein the cell recombinantly expresses a
geranylgeranyl diphosphate synthase (GGPPS) enzyme. 90. The method of claim 88 or 89, further comprising
altering the level of expression of one or more of the components of the non-mevalonate
(MEP) pathway, the copalyl diphosphate synthase (CPS) enzyme, the kaurene synthase (KS) enzyme and/or the geranylgeranyl diphosphate synthase (GGPPS) enzyme in the first improved cell to produce a second improved cell, and
comparing the amount of kaurene produced from the second improved cell to the amount of kaurene produced in the first improved cell, wherein a second improved cell that produces a higher amount of kaurene than the first improved cell is a cell that exhibits enhanced production of kaurene.
91. The method of any one of claims 87 to 90, wherein the copalyl diphosphate synthase (CPS) enzyme and/or the kaurene synthase (KS) enzyme is a Stevia enzyme, optionally a Stevia rebaudiana Bertoni enzyme.
92. The method of any one of claims 87 to 91, wherein the steviol glycoside is Reb A. 93. An isolated polypeptide comprising a kaurene oxidase (KO) enzyme, a kaurenoic acid 13-hydroxylase (KAH) enzyme, or a catalytically active portion thereof fused to a cytochrome P450 reductase enzyme, or a catalytically active portion thereof.
94. The isolated polypeptide of claim 93, wherein the cytochrome P450 reductase enzyme is a Taxus cytochrome P450 reductase (TCPR) or wherein the polypeptide is Stevia
NADPH:cytochrome P450 reductase (SCPR).
95. The isolated polypeptide of claim 94, wherein taxadiene 5 -hydroxylase and TCPR or SCPR are joined by a linker.
96. The isolated polypeptide of claim 95, wherein the linker is GSTGS (SEQ ID NO: 15)
97. The isolated polypeptide of any one of claims 93 to 96, wherein kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme, TCPR and/or SCPR are truncated to remove all or part of the transmembrane region.
98. The isolated polypeptide of any one of claims 93 to 97, wherein an additional peptide is fused to kaurene oxidase (KO) enzyme and/or kaurenoic acid 13-hydroxylase (KAH). 99. The isolated polypeptide of claim 98, wherein the additional peptide is from bovine 17a hydroxylase.
100. The isolated polypeptide of claim 99, wherein the peptide is MALLLAVF (SEQ ID NO: 16)
101. A nucleic acid molecule that encodes the polypeptide of any one of claims 93 to 100.
102. A cell that recombinantly expresses a polypeptide of any one of claims 93 to 100.
103. A method for increasing terpenoid production in a cell that produces at least one terpenoid selected from kaurene, steviol or steviol glycosides, comprising controlling the accumulation of indole in the cell or in a culture of the cells, thereby increasing terpenoid production in a cell.
104. The method of claim 103, wherein the cell is a bacterial cell. 105. The method of claim 104, wherein the cell is an Escherichia coli cell.
106. The method of claim 104, wherein the cell is a Gram-positive cell.
107. The method of claim 104, wherein the cell is a Bacillus cell.
108. The method of claim 103, wherein the cell is a yeast cell.
109. The method of claim 108, wherein the yeast cell is a Sacchawmyces cell. 110. The method of claim 108, wherein the yeast cell is a Yarrowia cell.
111. The method of claim 103, wherein the cell is an algal cell.
112. The method of claim 103, wherein the cell is a plant cell.
113. The method of claim 103, wherein the cell is a cell as recited in any of claims 47 to 86.
114. The method of any one of claims 103 to 113, wherein the step of controlling the accumulation of indole in the cell or in a culture of the cells comprises balancing the upstream non-mevalonate isoprenoid pathway with the downstream product synthesis pathways and/or modifying or regulating the indole pathway.
115. The method of any one of claims 103 to 114, wherein the step of controlling the accumulation of indole in the cell or in a culture of the cells comprises or further comprises removing the accumulated indole from the fermentation through chemical methods, optionally using absorbents or scavengers.
116. A method comprising measuring the amount or concentration of indole in a cell that produces at least one terpenoid selected from kaurene, steviol or steviol glycosides, or in a culture of the cells that produce one or more of the terpenoids. 117. The method of claim 116, wherein the method comprises measuring the amount or concentration of indole two or more times.
118. The method of claim 116 or claim 117, wherein the measured amount or concentration of indole is used to guide a process of producing one or more terpenoids.
119. The method of claim 116 or claim 117, wherein the measured amount or concentration of indole is used to guide strain construction.
120. The method of any one of claims 116 to 119, wherein the cell further recombinantly expresses a polypeptide of any one of claims 93 to 100.
121. A method for making a product containing a terpenoid selected from kaurene, a steviol, or a steviol glycoside, the method comprising:
increasing terpenoid production in a cell that produces one or more terpenoids by controlling the accumulation of indole in the cell or in a culture of the cells,
recovering the terpenoid from the cell, and optionally conducting one or more chemical or enzymatic steps on the recovered terpenoid; incorporating the recovered terpenoid or the terpenoid prepared through one or more chemical or enzymatic steps, into a product to thereby make the product containing a terpenoid.
122. The method of claim 121, wherein the cell is a bacterial cell.
123. The method of claim 121, wherein the cell is E. coli or B. subtilis.
124. The method of claim 121, wherein the step of controlling the accumulation of indole in the cell or in a culture of the cells comprises balancing an upstream non-mevalonate isoprenoid pathway with a downstream heterologous terpenoid synthesis pathway.
125. The method of claim 124, wherein the upstream non-mevalonate isoprenoid pathway is balanced with respect to the downstream heterologous terpenoid synthesis pathway by one or more of:
increasing gene copy number for one or more upstream or downstream pathway enzymes,
increasing or decreasing the expression level of the upstream and downstream pathway genes, as individual genes or as operons, using promoters with different strengths,
increasing or decreasing the expression level of the upstream and downstream pathways, as individual genes or as operons, using modifications to ribosomal binding sites,
replacing native genes in the pathway with heterologous genes coding for homologous enzymes,
codon-optimization of one or more heterologous enzymes in the upstream or downstream pathway,
amino acid mutations in one or more genes of the downstream and/or upstream pathway, or
modifying the order of upstream and downstream pathway genes in a heterologous operon. 126. The method of claim 125, wherein the cell comprises at least one additional copy of at least one of dxs, idi, ispD, and ispF.
127. The method of claim 126, wherein the cell comprises a heterologous dxs-idi-ispDF operon.
128. The method of claim 124, wherein indole accumulates in the culture at less than 100 mg/L.
129. The method of claim 128, wherein indole accumulates in the culture at less than 50 mg/L.
130. The method of claim 128, wherein indole accumulates in the culture at less than 10 mg/L.
131. The method of claim 128, wherein indole accumulates in the culture at less than 1 mg/L.
132. The method of claim 125, wherein the step of controlling the accumulation of indole in the cell or in a culture of the cells comprises modifying or regulating the indole pathway.
133. The method of claim 125, wherein the step of controlling the accumulation of indole in the cell or in a culture of the cells comprises or further comprises removing the accumulated indole from the cell culture through chemical methods.
134. The method of claim 133, wherein indole is removed from the culture at least in part using one or more absorbents or scavengers.
135. The method of claim 125, comprising measuring the amount of indole in the culture, or continuously or intermittently monitoring the amount of indole in the culture.
136. The method of claim 125, wherein the terpenoid is one or more of steviobioside, stevioside, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, and dulcoside A.
137. The method of claim 1, wherein the product is a food product or beverage, and the terpenoid is a taste enhancer or bitter blocker.
138. The method of claim 137, wherein the product is a soft drink, a cordial, milk, soy, mineral drink, canned fruit, jam, juice, ice cream, yogurt, dietary product, cake, biscuit, pastry, dessert, sugar free beer, alcoholic beverage, topping, sauce, chutney, spread, cereal, muesli bar, or confectionary.
139. The method of claim 137, wherein the food product is a dessert, yogurt, confectionary, sauce, pickle, delicacy, sweet corn, bread, or biscuit.
140. The method of claim 121, wherein the cell expresses a copalyl diphosphate synthase (CPS) enzyme, a kaurene synthase (KS) enzyme, a GGPPS enzyme, and the one or more components of the MEP pathway.
141. The method of claim 140, wherein the cell further expresses a kaurene oxidase (KO) enzyme, kaurenoic acid 13-hydroxylase (KAH) enzyme and/or catalytically active portion of KO and KAH, optionally fused to a cytochrome P450 reductase enzyme. 142. The method of claim 140 or 141, wherein the expression of the downstream pathway enzymes is balanced with respect to the one or more components of the MEP pathway to maximize production of the terpenoid.
143. The method of any one of claims 121 to 142, wherein the cell further expresses one or more UDP-glycosyltransferases (UGTs) or a catalytically active portion thereof.
144. The method of claim 143, wherein the UDP-glycosyltransferase (UGT) enzyme(s) is a Stevia enzyme. 145. The method of claim 144, wherein the UDP-glycosyltransferase (UGT) enzyme(s) is a Stevia rebaudiana Bertoni enzyme.
146. The method of any one of claims 143 to 145, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are expressed together on an operon. 147. The method of any one of claims 143 to 146, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are expressed from one or more plasmids.
148. The method of any one of claims 143 to 146, wherein the gene(s) encoding one or more of the UDP-glycosyltransferases (UGTs) or a catalytically active portion are incorporated into the genome of the cell.
149. The method of claim 121, wherein the one or more enzymatic steps comprise glycosyltransferase steps.
PCT/US2011/062428 2010-11-30 2011-11-29 Microbial production of natural sweeteners, diterpenoid steviol glycosides WO2012075030A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2819253A CA2819253A1 (en) 2010-11-30 2011-11-29 Microbial production of natural sweeteners, diterpenoid steviol glycosides
EP11793960.3A EP2645847B1 (en) 2010-11-30 2011-11-29 Microbial production of natural sweeteners, diterpenoid steviol glycosides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41835710P 2010-11-30 2010-11-30
US61/418,357 2010-11-30
US13/249,388 US8927241B2 (en) 2009-11-10 2011-09-30 Microbial engineering for the production of chemical and pharmaceutical products from the isoprenoid pathway
US13/249,388 2011-09-30

Publications (1)

Publication Number Publication Date
WO2012075030A1 true WO2012075030A1 (en) 2012-06-07

Family

ID=45218919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/062428 WO2012075030A1 (en) 2010-11-30 2011-11-29 Microbial production of natural sweeteners, diterpenoid steviol glycosides

Country Status (4)

Country Link
US (1) US9284570B2 (en)
EP (1) EP2645847B1 (en)
CA (1) CA2819253A1 (en)
WO (1) WO2012075030A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575432A1 (en) 2010-06-02 2013-04-10 Evolva Nutrition, Inc Recombinant production of steviol glycosides
WO2013022989A3 (en) * 2011-08-08 2013-07-04 Evolva Sa Recombinant production of steviol glycosides
WO2013110673A1 (en) * 2012-01-23 2013-08-01 Dsm Ip Assets B.V. Diterpene production
WO2013180306A1 (en) * 2012-05-30 2013-12-05 サントリーホールディングス株式会社 Steviol glycosyltransferase and gene encoding same
WO2014122227A3 (en) * 2013-02-06 2014-11-20 Evolva Sa Methods for improved production of rebaudioside d and rebaudioside m
WO2014191581A2 (en) * 2013-05-31 2014-12-04 Dsm Ip Assets B.V. Microorganisms for diterpene production
WO2015007748A1 (en) * 2013-07-15 2015-01-22 Dsm Ip Assets B.V. Diterpene production
WO2015139599A1 (en) * 2014-03-20 2015-09-24 中国科学院上海生命科学研究院 New 13a-kaurenoic acid hydroxylase, encoding gene and uses thereof
WO2016038095A3 (en) * 2014-09-09 2016-05-12 Evolva Sa Production of steviol glycosides in recombinant hosts
WO2016073740A1 (en) * 2014-11-05 2016-05-12 Manus Biosynthesis, Inc. Microbial production of steviol glycosides
WO2017034942A1 (en) 2015-08-21 2017-03-02 Manus Biosynthesis, Inc. Increasing productivity of e. coli host cells that functionally express p450 enzymes
WO2018104238A1 (en) * 2016-12-08 2018-06-14 Dsm Ip Assets B.V. Kaurenoic acid hydroxylases
US10017804B2 (en) 2013-02-11 2018-07-10 Evolva Sa Efficient production of steviol glycosides in recombinant hosts
WO2018140778A1 (en) 2017-01-26 2018-08-02 Manus Bio, Inc. Metabolic engineering for microbial production of terpenoid products
US10364450B2 (en) 2015-01-30 2019-07-30 Evolva Sa Production of steviol glycoside in recombinant hosts
US10421983B2 (en) 2014-08-11 2019-09-24 Evolva Sa Production of steviol glycosides in recombinant hosts
WO2019232025A2 (en) 2018-05-29 2019-12-05 Massachusetts Institute Of Technology Microbial engineering for the production of isoprenoids
CN111088254A (en) * 2019-11-05 2020-05-01 中国农业科学院生物技术研究所 Exogenous gene fixed-point quantitative timing expression system based on fungal operon
EP3526329A4 (en) * 2016-10-12 2020-05-27 Reliance Industries Limited Method for production of isoprene recombinant microorganism, gene construct, vector and application thereof
US10815514B2 (en) 2016-05-16 2020-10-27 Evolva Sa Production of steviol glycosides in recombinant hosts
US10837041B2 (en) 2015-08-07 2020-11-17 Evolva Sa Production of steviol glycosides in recombinant hosts
US10947515B2 (en) 2015-03-16 2021-03-16 Dsm Ip Assets B.V. UDP-glycosyltransferases
US10982249B2 (en) 2016-04-13 2021-04-20 Evolva Sa Production of steviol glycosides in recombinant hosts
US11396669B2 (en) 2016-11-07 2022-07-26 Evolva Sa Production of steviol glycosides in recombinant hosts

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9392799B2 (en) 2011-02-17 2016-07-19 Purecircle Sdn Bhd Glucosyl stevia composition
US9386797B2 (en) 2011-02-17 2016-07-12 Purecircle Sdn Bhd Glucosyl stevia composition
US8790730B2 (en) 2005-10-11 2014-07-29 Purecircle Usa Process for manufacturing a sweetener and use thereof
US9107436B2 (en) 2011-02-17 2015-08-18 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US8257948B1 (en) 2011-02-17 2012-09-04 Purecircle Usa Method of preparing alpha-glucosyl Stevia composition
US8318459B2 (en) 2011-02-17 2012-11-27 Purecircle Usa Glucosyl stevia composition
ES2575790T3 (en) 2009-11-10 2016-07-01 Massachusetts Insitute Of Technology Microbial engineering for the preparation of chemical and pharmaceutical products from the isoprenoid pathway
US8927241B2 (en) 2009-11-10 2015-01-06 Massachusetts Institute Of Technology Microbial engineering for the production of chemical and pharmaceutical products from the isoprenoid pathway
BR112012011382B1 (en) 2009-11-12 2018-02-06 Purecircle Usa Inc. METHOD FOR PRODUCING A STEVIA GRANULATE SWEETENER AND SWEETENER
EP4108668A1 (en) 2010-03-12 2022-12-28 PureCircle USA Inc. High-purity steviol glycosides
US10696706B2 (en) 2010-03-12 2020-06-30 Purecircle Usa Inc. Methods of preparing steviol glycosides and uses of the same
BR112013014589B1 (en) 2010-12-13 2019-04-02 Purecircle Usa Inc. METHOD FOR PREPARING A HIGHLY SOLUBLE REBAUDIOSIDE COMPOSITION
US9510611B2 (en) 2010-12-13 2016-12-06 Purecircle Sdn Bhd Stevia composition to improve sweetness and flavor profile
BR112013020511B1 (en) 2011-02-10 2018-05-22 Purecircle Usa Inc. REBAUDIOSIDA B COMPOSITION AND ITS PRODUCTION PROCESS AS WELL AS SWEET AND FLAVOR COMPOSITIONS, FOOD INGREDIENT, DRINK AND COSMETIC PRODUCT UNDERSTANDING THE DIET REBAUDIOSIDA B COMPOSITION
US9474296B2 (en) 2011-02-17 2016-10-25 Purecircle Sdn Bhd Glucosyl stevia composition
US9603373B2 (en) 2011-02-17 2017-03-28 Purecircle Sdn Bhd Glucosyl stevia composition
US11690391B2 (en) 2011-02-17 2023-07-04 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US9894922B2 (en) 2011-05-18 2018-02-20 Purecircle Sdn Bhd Glucosyl rebaudioside C
PL2713763T3 (en) 2011-05-31 2019-10-31 Purecircle Usa Inc Stevia composition
US9877501B2 (en) 2011-06-03 2018-01-30 Purecircle Sdn Bhd Stevia composition
US9771434B2 (en) 2011-06-23 2017-09-26 Purecircle Sdn Bhd Products from stevia rebaudiana
US10480019B2 (en) 2011-08-10 2019-11-19 Purecircle Sdn Bhd Process for producing high-purity rubusoside
MX2014002462A (en) 2011-09-07 2014-05-07 Purecircle Usa Inc Highly soluble stevia sweetener.
EP2852296B1 (en) 2012-05-22 2021-12-15 PureCircle SDN BHD Process for producing a high-purity steviol glycoside
US9752174B2 (en) 2013-05-28 2017-09-05 Purecircle Sdn Bhd High-purity steviol glycosides
US9611498B2 (en) * 2012-09-29 2017-04-04 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Method for producing stevioside compounds by microorganism
WO2014086890A1 (en) * 2012-12-05 2014-06-12 Evolva Sa Steviol glycoside compositions sensory properties
US10952458B2 (en) 2013-06-07 2021-03-23 Purecircle Usa Inc Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier
ES2817049T5 (en) 2013-06-07 2023-11-10 Purecircle Usa Inc Stevia extract containing selected steviol glycosides as a taste, flavor and sweetness profile modifier
US10273519B2 (en) * 2013-07-23 2019-04-30 Dsm Ip Assets B.V. Diterpene production in Yarrowia
JP6735750B2 (en) 2014-08-21 2020-08-05 マナス バイオシンセシス インコーポレイテッド Oxygen-containing terpene production method
CN107105686B (en) 2014-09-02 2021-12-24 谱赛科美国股份有限公司 Stevia extract rich in rebaudioside D, E, N and/or O and preparation method thereof
JP6854238B2 (en) * 2014-10-03 2021-04-14 コナゲン インコーポレイテッド Non-caloric sweeteners and methods for synthesis
EP3303552A4 (en) 2015-05-29 2019-01-16 Cargill, Incorporated Fermentation methods for producing steviol glycosides with multi-phase feeding
EP4134442A1 (en) 2015-05-29 2023-02-15 Cargill, Incorporated Fermentation methods for producing steviol glycosides using high ph
AU2016271125A1 (en) 2015-05-29 2017-12-21 Cargill, Incorporated Heat treatment to produce glycosides
AU2016301190A1 (en) 2015-08-06 2018-02-15 Cargill, Incorporated Fermentation methods for producing steviol glycosides
RU2731068C2 (en) 2015-10-26 2020-08-28 ПЬЮРСЁРКЛ ЮЭсЭй ИНК. Steviol glycoside compositions
MX2018007241A (en) 2015-12-15 2018-11-09 Purecircle Usa Inc Steviol glycoside compositions.
MX2019009135A (en) 2017-02-03 2019-10-09 Manus Bio Inc Metabolic engineering for microbial production of terpenoid products.
US11365417B2 (en) 2017-09-12 2022-06-21 Bio Capital Holdings, LLC Biological devices and methods of use thereof to produce steviol glycosides
WO2019099649A1 (en) * 2017-11-20 2019-05-23 Manus Bio, Inc. Microbial host cells for production of steviol glycosides
WO2020232814A1 (en) * 2019-05-20 2020-11-26 江苏施宇甜生物科技有限公司 Recombinant bacillus subtilis used for producing udp-glycosyltransferase, and recombination method therefor
CN114457051A (en) * 2020-11-09 2022-05-10 江苏施宇甜生物科技有限公司 Method for producing UDP-glycosyltransferase by fermenting recombinant bacillus subtilis
CN117015611A (en) 2021-03-01 2023-11-07 嘉吉公司 Xylosylated steviol glycosides and enzymatic process for production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072323A1 (en) * 2001-01-05 2004-04-15 Matsuda Seiichi P.T. Diterpene-producing unicellular organism
US20100297722A1 (en) * 2009-05-20 2010-11-25 Board Of Trustees Of Southern Illinois University Transgenic moss producing terpenoids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038571A1 (en) 1996-04-15 1997-10-23 Washington State University Research Foundation Compositions and methods for taxol biosynthesis
US7256014B2 (en) 2005-07-27 2007-08-14 E. I. Du Pont De Nemours And Company Method to increase hydrophobic compound titer in a recombinant microorganism
WO2007140339A2 (en) 2006-05-26 2007-12-06 Amyris Biotechnologies, Inc. Production of isoprenoids
WO2008128159A1 (en) * 2007-04-16 2008-10-23 Amyris Biotechnologies, Inc. Production of isoprenoids
ES2575790T3 (en) 2009-11-10 2016-07-01 Massachusetts Insitute Of Technology Microbial engineering for the preparation of chemical and pharmaceutical products from the isoprenoid pathway
US8927241B2 (en) 2009-11-10 2015-01-06 Massachusetts Institute Of Technology Microbial engineering for the production of chemical and pharmaceutical products from the isoprenoid pathway
US9562251B2 (en) * 2010-06-02 2017-02-07 Evolva Sa Production of steviol glycosides in microorganisms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072323A1 (en) * 2001-01-05 2004-04-15 Matsuda Seiichi P.T. Diterpene-producing unicellular organism
US20100297722A1 (en) * 2009-05-20 2010-11-25 Board Of Trustees Of Southern Illinois University Transgenic moss producing terpenoids

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
A. RICHMAN ET AL., THE PLANT JOURNAL, vol. 41, 2005, pages 56
A. S. RICHMAN; M. GIJZEN; A. N. STARRATT; Z. YANG; J. E. BRANDLE, THE PLANT JOURNAL, vol. 19, 1999, pages 411
AJIKUMAR PARAYIL KUMARAN ET AL: "Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in Escherichia coli", SCIENCE (WASHINGTON D C), vol. 330, no. 6000, October 2010 (2010-10-01), pages 70 - 74, XP002618146, ISSN: 0036-8075 *
AJIKUMAR, P. K. ET AL., SCIENCE, vol. 330, October 2010 (2010-10-01), pages 70 - 4
BRANDLE ET AL: "Steviol glycoside biosynthesis", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 68, no. 14, 1 July 2007 (2007-07-01), pages 1855 - 1863, XP022145443, ISSN: 0031-9422, DOI: 10.1016/J.PHYTOCHEM.2007.02.010 *
C. ULBRICHT ET AL., CARDIOVASCULAR & HEMATOLOGICAL AGENTS IN MEDICINAL CHEMISTRY, vol. 8, pages 113
D. G. GIBSON ET AL., SCIENCE, vol. 329, 2 July 2010 (2010-07-02), pages 52
EFFENDI LEONARDA ET AL: "Combining metabolic and protein engineering of a terpenoid biosynthetic pathway for overproduction and selectivity control", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 107, no. 31, 3 August 2010 (2010-08-03), pages 13654 - 13659, XP002617176, ISSN: 0027-8424, [retrieved on 20100719], DOI: 10.1073/PNAS.1006138107 *
J. GEUNS, PHYTOCHEMISTRY, vol. 64, 2003, pages 913
J. M. C. GEUNS, EUSTAS, 2007, Retrieved from the Internet <URL:http:llwww.eustas.orglSteviol_glycosides_summary_application.pdfSteviol>
K. E. TYO; H. S. ALPER; G. N. STEPHANOPOULOS, TRENDS BIOTECHNOL, vol. 25, March 2007 (2007-03-01), pages 132
KIRBY JAMES ET AL: "Biosynthesis of plant isoprenoids: perspectives for microbial engineering", ANNUAL REVIEW OF PLANT BIOLOGY,, vol. 60, 1 January 2009 (2009-01-01), pages 335 - 355, XP009143317, DOI: 10.1146/ANNUREV.ARPLANT.043008.091955 *
KLEIN-MARCUSCHAMER ET AL: "Engineering microbial cell factories for biosynthesis of isoprenoid molecules: beyond lycopene", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 25, no. 9, 23 August 2007 (2007-08-23), pages 417 - 424, XP022210242, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2007.07.006 *
M. C. CARAKOSTAS; L. L. CURRY; A. C. BOILEAU; D. J. BRUSICK, FOOD AND CHEMICAL TOXICOLOGY, vol. 46, 2008, pages 1
M. C. CARAKOSTAS; L. L. CURRY; A. C. BOILEAU; D. J. BRUSICK, FOOD CHEM TOXICOL, vol. 46, no. 7, July 2008 (2008-07-01)
M. SHARMA; N. K. THAKRAL; S. THAKRAL, NATURAL PRODUCT RADIANCE, vol. 8, 2009, pages 181
P. K. AJIKUMAR ET AL., MOL PHARM, vol. 5, March 2008 (2008-03-01), pages 167
PARAYIL KUMARAN AJIKUMAR ET AL: "Terpenoids: opportunities for biosynthesis of natural product drugs using engineered microorganisms", MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY, US, vol. 5, no. 2, 1 March 2008 (2008-03-01), pages 167 - 190, XP002617175, ISSN: 1543-8384, [retrieved on 20080321], DOI: 10.1021/MP700151B *
S. D. SINGH; G. P. RAO, SUGAR TECH, vol. 7, 2005, pages 17
S. R. MISHRA P.; KUMAR U.; PRAKASH V, GLOBAL JOURNAL OF BIOTECHNOLOGY & BIOCHEMISTRY, vol. 5, 2010, pages 62
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
TANIA V HUMPHREY ET AL: "Spatial Organisation of Four Enzymes from Stevia rebaudiana that are Involved in Steviol Glycoside Synthesis", PLANT MOLECULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 61, no. 1-2, 1 May 2006 (2006-05-01), pages 47 - 62, XP019405427, ISSN: 1573-5028, DOI: 10.1007/S11103-005-5966-9 *
V. E. BALDERAS-HERNANDEZ ET AL., MICROB CELL FACT, vol. 8, 2009, pages 19

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017079739A (en) * 2010-06-02 2017-05-18 エボルバ， インク．Ｅｖｏｌｖａ， Ｉｎｃ． Recombinant production of steviol glycosides
JP2013533736A (en) * 2010-06-02 2013-08-29 エボルバ ニュートリション， インク． Recombinant production of steviol glycosides
EP2575432A4 (en) * 2010-06-02 2014-01-22 Evolva Inc Recombinant production of steviol glycosides
US9562251B2 (en) 2010-06-02 2017-02-07 Evolva Sa Production of steviol glycosides in microorganisms
EP2575432A1 (en) 2010-06-02 2013-04-10 Evolva Nutrition, Inc Recombinant production of steviol glycosides
US10392644B2 (en) 2010-06-02 2019-08-27 Evolva Sa Production of steviol glycosides in microorganisms
WO2013022989A3 (en) * 2011-08-08 2013-07-04 Evolva Sa Recombinant production of steviol glycosides
EP3009508A1 (en) * 2011-08-08 2016-04-20 Evolva SA Recombinant production of steviol glycosides
US9631215B2 (en) 2011-08-08 2017-04-25 Evolva Sa Recombinant production of steviol glycosides
EP3792350A1 (en) * 2011-08-08 2021-03-17 Evolva SA Recombinant production of steviol glycosides
US10435730B2 (en) 2011-08-08 2019-10-08 Evolva Sa Recombinant production of steviol glycosides
WO2013110673A1 (en) * 2012-01-23 2013-08-01 Dsm Ip Assets B.V. Diterpene production
EP3444338A1 (en) * 2012-01-23 2019-02-20 DSM IP Assets B.V. Diterpene production
JPWO2013180306A1 (en) * 2012-05-30 2016-01-21 サントリーホールディングス株式会社 Steviol glycoside enzyme and gene encoding the same
US10113155B2 (en) 2012-05-30 2018-10-30 Suntory Holdings Limited Steviol glycosyltransferase and gene encoding same
WO2013180306A1 (en) * 2012-05-30 2013-12-05 サントリーホールディングス株式会社 Steviol glycosyltransferase and gene encoding same
CN105051195A (en) * 2013-02-06 2015-11-11 埃沃尔瓦公司 Methods for improved production of rebaudioside d and rebaudioside m
US11530431B2 (en) 2013-02-06 2022-12-20 Evolva Sa Methods for improved production of Rebaudioside D and Rebaudioside M
US10612066B2 (en) 2013-02-06 2020-04-07 Evolva Sa Methods for improved production of rebaudioside D and rebaudioside M
WO2014122227A3 (en) * 2013-02-06 2014-11-20 Evolva Sa Methods for improved production of rebaudioside d and rebaudioside m
US9957540B2 (en) 2013-02-06 2018-05-01 Evolva Sa Methods for improved production of Rebaudioside D and Rebaudioside M
EP3892728A1 (en) * 2013-02-06 2021-10-13 Evolva SA Methods for improved production of rebaudioside d and rebaudioside m
US11021727B2 (en) 2013-02-11 2021-06-01 Evolva Sa Efficient production of steviol glycosides in recombinant hosts
US10017804B2 (en) 2013-02-11 2018-07-10 Evolva Sa Efficient production of steviol glycosides in recombinant hosts
WO2014191581A3 (en) * 2013-05-31 2015-03-05 Dsm Ip Assets B.V. Microorganisms for diterpene production
US11725223B2 (en) 2013-05-31 2023-08-15 Dsm Ip Assets B.V. Microorganisms for diterpene production
EP3502264A3 (en) * 2013-05-31 2019-11-06 DSM IP Assets B.V. Microorganisms for diterpene production
US10689681B2 (en) 2013-05-31 2020-06-23 Dsm Ip Assets B.V. Microorganisms for diterpene production
WO2014191581A2 (en) * 2013-05-31 2014-12-04 Dsm Ip Assets B.V. Microorganisms for diterpene production
EP3885443A1 (en) * 2013-07-15 2021-09-29 DSM IP Assets B.V. Diterpene production
WO2015007748A1 (en) * 2013-07-15 2015-01-22 Dsm Ip Assets B.V. Diterpene production
WO2015139599A1 (en) * 2014-03-20 2015-09-24 中国科学院上海生命科学研究院 New 13a-kaurenoic acid hydroxylase, encoding gene and uses thereof
US11168343B2 (en) 2014-08-11 2021-11-09 Evolva Sa Production of steviol glycosides in recombinant hosts
US10421983B2 (en) 2014-08-11 2019-09-24 Evolva Sa Production of steviol glycosides in recombinant hosts
US11466302B2 (en) 2014-09-09 2022-10-11 Evolva Sa Production of steviol glycosides in recombinant hosts
WO2016038095A3 (en) * 2014-09-09 2016-05-12 Evolva Sa Production of steviol glycosides in recombinant hosts
US10612064B2 (en) 2014-09-09 2020-04-07 Evolva Sa Production of steviol glycosides in recombinant hosts
US10463062B2 (en) 2014-11-05 2019-11-05 Manus Bio Inc. Microbial production of steviol glycosides
US11819042B2 (en) 2014-11-05 2023-11-21 Manus Bio Inc. Uridine diphosphate-dependent glycosyltransferase circular permutants
US10743567B2 (en) 2014-11-05 2020-08-18 Manus Bio Inc. Microbial production of steviol glycosides
WO2016073740A1 (en) * 2014-11-05 2016-05-12 Manus Biosynthesis, Inc. Microbial production of steviol glycosides
US11041183B2 (en) 2015-01-30 2021-06-22 Evolva Sa Production of steviol glycoside in recombinant hosts
US11807888B2 (en) 2015-01-30 2023-11-07 Evolva Sa Production of steviol glycoside in recombinant hosts
US10364450B2 (en) 2015-01-30 2019-07-30 Evolva Sa Production of steviol glycoside in recombinant hosts
US10947515B2 (en) 2015-03-16 2021-03-16 Dsm Ip Assets B.V. UDP-glycosyltransferases
US11459548B2 (en) 2015-03-16 2022-10-04 Dsm Ip Assets B.V. UDP-glycosyltransferases
US10837041B2 (en) 2015-08-07 2020-11-17 Evolva Sa Production of steviol glycosides in recombinant hosts
WO2017034942A1 (en) 2015-08-21 2017-03-02 Manus Biosynthesis, Inc. Increasing productivity of e. coli host cells that functionally express p450 enzymes
US11821015B2 (en) 2016-04-13 2023-11-21 Evolva Sa Production of steviol glycosides in recombinant hosts
US10982249B2 (en) 2016-04-13 2021-04-20 Evolva Sa Production of steviol glycosides in recombinant hosts
US10815514B2 (en) 2016-05-16 2020-10-27 Evolva Sa Production of steviol glycosides in recombinant hosts
EP3526329A4 (en) * 2016-10-12 2020-05-27 Reliance Industries Limited Method for production of isoprene recombinant microorganism, gene construct, vector and application thereof
US11396669B2 (en) 2016-11-07 2022-07-26 Evolva Sa Production of steviol glycosides in recombinant hosts
CN110072995A (en) * 2016-12-08 2019-07-30 帝斯曼知识产权资产管理有限公司 Kaurenic acid hydroxylase
US11913034B2 (en) 2016-12-08 2024-02-27 Dsm Ip Assets B.V. Kaurenoic acid hydroxylases
US11104886B2 (en) 2016-12-08 2021-08-31 Dsm Ip Assets B.V. Kaurenoic acid hydroxylases
WO2018104238A1 (en) * 2016-12-08 2018-06-14 Dsm Ip Assets B.V. Kaurenoic acid hydroxylases
CN110072995B (en) * 2016-12-08 2024-05-10 帝斯曼知识产权资产管理有限公司 Kaurenoic acid hydroxylase
WO2018140778A1 (en) 2017-01-26 2018-08-02 Manus Bio, Inc. Metabolic engineering for microbial production of terpenoid products
CN110869500B (en) * 2017-01-26 2023-10-27 马努斯生物合成股份有限公司 Metabolic engineering for microbial production of terpenoid products
CN110869500A (en) * 2017-01-26 2020-03-06 马努斯生物合成股份有限公司 Metabolic engineering for microbial production of terpenoid products
WO2019232025A2 (en) 2018-05-29 2019-12-05 Massachusetts Institute Of Technology Microbial engineering for the production of isoprenoids
CN111088254B (en) * 2019-11-05 2021-11-23 中国农业科学院生物技术研究所 Endogenous carried exogenous gene efficient controllable expression system
CN111088254A (en) * 2019-11-05 2020-05-01 中国农业科学院生物技术研究所 Exogenous gene fixed-point quantitative timing expression system based on fungal operon

Also Published As

Publication number Publication date
US20120164678A1 (en) 2012-06-28
EP2645847B1 (en) 2018-01-17
EP2645847A1 (en) 2013-10-09
US9284570B2 (en) 2016-03-15
CA2819253A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
US9284570B2 (en) Microbial production of natural sweeteners, diterpenoid steviol glycosides
US11819042B2 (en) Uridine diphosphate-dependent glycosyltransferase circular permutants
US20240068002A1 (en) Microorganisms for diterpene production
DK2806754T3 (en) Diterpene PREPARATION
EP3021689B1 (en) Diterpene production
AU2017258907A1 (en) Recombinant production of steviol glycosides
US20210032669A1 (en) Microbial production of triterpenoids including mogrosides
CN108138152B (en) Kaurenoic acid hydroxylase
CN110892068B (en) UDP-glycosyltransferase
CN109890961B (en) Geranylgeranyl pyrophosphate synthase
CN110072995B (en) Kaurenoic acid hydroxylase
US20230042171A1 (en) Microbial production of mogrol and mogrosides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11793960

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2819253

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE